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ABSTRACT 
A Novel Phosphodiesterase of the GdpP Family Modulates Cyclic di-
AMP Levels in Response to Cell Membrane Stress in Daptomycin-
Resistant Enterococci 
by 
Xu Wang 
Antimicrobial resistance is a serious and growing threat to public health. The 
Centers for Disease Control estimates that at least 2 million people contract serious 
infections each year resulting in at least 23,000 deaths each year in the United States 
alone. To develop more effective treatments, it is important to understand the 
fundamental biology underlying the mechanisms of antibiotic resistance. 
Substitutions in the LiaFSR membrane stress response pathway are frequently 
associated with emergence of antimicrobial peptide resistance in both Enterococcus 
faecalis and Enterococcus faecium. Cyclic di-AMP (c-di-AMP) is an important signal 
molecule that affects many aspects of bacterial physiology including stress response. 
We have previously identified a mutation in a gene (designated yybT) of E. faecalis 
that was associated with development of daptomycin resistance. The adaptive 
mutation produced a change at position 440 in the predicted protein (yybTI440S). 
Here, we show that intracellular cyclic di-AMP signaling is present in enterococci 
and, based upon in vitro physicochemical characterization, we show that E. faecalis 
yybT encodes a cyclic dinucleotide phosphodiesterase of the GdpP family that 
exhibits specific activity toward c-di-AMP by hydrolyzing it to 5’pApA. The E. 
 
 
faecalis GdpPI440S substitution reduces cyclic di-AMP phosphodiesterase activity 
more than 11-fold leading to further increases in cyclic di-AMP levels. Additionally, 
deletions of liaR (encoding the response regulator of the LiaFSR system) that lead to 
daptomycin hypersusceptibility in both E. faecalis and E. faecium also resulted in 
increased cyclic-di-AMP levels suggesting that changes in the LiaFSR stress response 
pathway are linked to broader physiological changes. Taken together, our data show 
that modulation of cyclic di-AMP pools is strongly associated with antibiotic-
induced cell membrane stress response via changes in GdpP activity and signaling 
through the LiaFSR system.  
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Chapter 1 
Introduction 
1.1. E. faecalis GdpP is a putative cyclic di-AMP-specific 
phosphodiesterase. 
GdpP (GGDEF domain protein containing phosphodiesterase) is a multi-
domain protein containing two putative N-terminal transmembrane helices, a 
putative Per-Arnt-Sim (PAS) domain, a GGDEF domain and a DHH domain with a 
DHHA1 subdomain (Figure 1.1) (Rao et al., 2010). GdpP has been identified in 
several Gram-positive bacteria including Bacillus subtilis (Rao et al., 2010), 
Lactococcus lactis (Smith et al., 2012), Streptococcus pyogenes (Cho and Kang, 2013) 
and Staphylococcus aureus (Corrigan et al., 2011) with roles in bacterial growth and 
virulence.  
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In a previous study about Enterococcus faecalis (E. faelicas) evolutionary 
trajectories to antibiotic daptomycin (DAP) resistance, Miller et al. identified 
mutation I440S in a previously unidentified gene, designated yybT (Miller et al., 
2013). Based on primary sequence alignment, I reasoned that YybT might be a 
member of the GdpP family (E. faecalis yybT will be referred to as Efc gdpP hereafter) 
(Corrigan et al., 2011). Since GdpPI440S was identified in the DAP-resistant E. faecalis, 
I postulated GdpP was also active in E. faecalis, and wanted to study the structure 
and functions of Efc GdpP and how the I440S adaptive mutation affects GdpP 
activity. From studies on the individual domains of GdpP homologs, several 
activities have been described. 
 
Figure 1.1 Domain organization of E. faecalis GdpP. Efc GdpP is a multi-domain 
protein containing two putative N-terminal transmembrane helices, a Per-Arnt-Sim 
(PAS) domain, a GGDEF domain and a DHH domain with a DHHA1 subdomain. The 
DHH/DHHA1 domain has putative c-di-AMP phosphodiesterase active site while the 
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GGDEF domain has putative ATPase activity. The daptomycin adaptive mutation I440S 
is in the DHH domain. 
 
1.1.1. Efc GdpP PAS domain is a putative signal sensor domain. 
PAS domains are important signaling input modules usually fused to a signal 
transduction or sensory protein (Henry and Crosson, 2011). They have been shown 
to detect a variety of environmental stimuli and transmit the information to other 
signaling output domains in the protein (Henry and Crosson, 2011). B. subtilis GdpP 
(BsGdpP) and G. thermodenitrificans GdpP (GtGdpP) have been demonstrated to 
have heme-binding PAS domains (Rao et al., 2010, 2011). The binding of heme to 
PAS domain can inhibit the activities of GGDEF domain and DHH/DHHA1 domain in 
BsGdpP (Rao et al., 2010). No known ligand for the PAS domain of Efc GdpP has been 
established. 
1.1.2. Efc GdpP GGDEF domain is a putative ATPase domain. 
GGDEF was referred to the highly conserved Gly-Gly-Asp-Glu-Phe motif in 
this domain (Hecht and Newton, 1995). GGDEF domains typically have a diguanylate 
cyclase (DGC) activity to synthesize c-di-GMP from 2 GTP molecules (Rao et al., 
2010). However, the GGDEF domain in BsGdpP lacks the essential GGDEF motif, and 
has weak ATPase activity (Rao et al., 2010).  
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GGDEF domains were also recently reported to have a diadenylate cyclase 
activity that can synthesize cyclic di-AMP (c-di-AMP) from two ATP molecules 
(Hallberg et al., 2016). Three GGDEF domain proteins from Gram-negative bacteria, 
Geobacter sulfurreducens HyprA (also referred to as GSU1658), Bdellovibrio 
bacteriovorus DgcA (also referred to as Bd0367), and Myxococcus xanthus HyprB 
(also referred to as MXAN-2643), showed diadenylate cyclase activity in vitro and 
when they were over expressed in E. coli (Hallberg et al., 2016).  However, since c-
di-AMP has not been identified in Gram-negative bacteria, whether these 
observations are physiologically relevant will require further investigation. 
Nevertheless, it suggests Efc GdpP can synthesize c-di-AMP under certain conditions. 
1.1.3. Efc GdpP DHH/DHHA1 domain is a putative phosphodiesterase domain. 
The Asp-His-His (DHH/DHHA1) domain of BsGdpP has a cyclic-dinucleotide 
(c-di-AMP and c-di-GMP) phosphodiesterase (PDE) activity in vitro, and can 
hydrolyze c-di-AMP and c-di-GMP to 5’pApA and 5’pGpG respectively (Rao et al., 
2010). S. aureus GdpP (SaGdpP) has c-di-AMP-specific PDE activity in vivo (Corrigan 
et al., 2011). The signaling molecule, ppGpp, can inhibit BsGdpP PDE activity (Rao et 
al., 2010). Using a bioinformatic approach I was able to identify a potential 
DHH/DHHA1 domain in Efc GdpP suggesting a potential c-di-AMP 
phosphodiesterase activity. 
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1.2. Cyclic di-AMP is a new second messenger identified in some 
Gram-positive bacteria. 
Interesting, cyclic di-AMP (c-di-AMP) is a putative substrate, as well as a putative 
product, of Efc GdpP. c-di-AMP is a recently discovered second messenger molecule 
(Figure 1.2). Since c-di-AMP could only be synthesized chemically in the twentieth 
century, the microbiological role of c-di-AMP was largely unknown until Witte et al. 
first discovered a c-di-AMP synthase in B. subtilis in 2008 (Bejerano-Sagie et al., 
2006; Römling, 2008; Witte et al., 2008). Later on, c-di-AMP was identified in 
several other Gram-positive bacteria including Listeria monocytogenes (Witte et al., 
2013), Staphylococcus  aureus (Corrigan et al., 2011), Streptococcus pyogenes (Cho 
and Kang, 2013), and Streptococcus pneumoniae (Bai et al., 2013).  
 
Figure 1.2 Structure of cyclic di-AMP. Figure is produced by Chemdraw 
Professional.  
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1.2.1. Synthesis and degradation of c-di-AMP 
1.2.1.1. c-di-AMP is synthesized by diadenyl cyclase. 
The ability to directly synthesize c-di-AMP from two ATP or ADP was first 
identified in a specific diadenylate cyclase (DAC) domain (Bai et al., 2012; Witte et 
al., 2008). To date, three DAC domain proteins have been discovered, including the 
most common DAC synthase referred to as c-di-AMP synthase A (CdaA, also referred 
to as YbbP), the sporulation-specific synthase CdaS (also referred to as YojJ), and the 
DNA integrity scanning protein A (Dis A) (Corrigan et al., 2013; Mehne et al., 2013, 
2014; Oppenheimer-Shaanan et al., 2011a; Witte et al., 2008).  
As mentioned above (Section 1.1.2), some GGDEF domains in Gram-negative 
bacteria also showed diadenylate cyclase activity (Hallberg et al., 2016) 
1.2.1.2. c-di-AMP is hydrolyzed by phosphodiesterases. 
In vivo levels of c-di-AMP are not only maintained by diadenyl cyclases but 
also by phosphodiesterases. The Asp-His-His (DHH/DHHA1) domain and His-Asp 
(HD) domain hydrolyze c-di-AMP to 5’pApA or AMP (Huynh et al., 2015; Rao et al., 
2010). A study of L. monocytogenes c-di-AMP phosphodiesterases showed that 
DHH/DHHA1 family phosphodiesterases are more important than HD family 
phosphodiesterases for bacterial virulence and intracellular growth (Huynh et al., 
2015).  
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1.2.2. Molecular mechanism of c-di-AMP signaling 
Genes encoding c-di-AMP synthases and phosphodiesterases are widespread 
in Gram-positive bacteria and some archaea (Rao et al., 2010; Römling, 2008) and 
are usually found together suggesting a dynamic interplay of activities that 
maintains the steady-state level of c-di-AMP in vivo. c-di-AMP has been shown to 
bind both of RNAs and proteins (Corrigan et al., 2013; Nelson et al., 2013) and 
therefore there are many potential downstream targets for c-di-AMP signaling. As a 
second massager, c-di-AMP not only participates in regulating metabolism, but also 
quorum sensing consistent with a broad role in bacterial physiology.   
1.2.2.1. c-di-AMP can regulate gene expression by binding to an RNA 
riboswitch. 
c-di-AMP can regulate cell signaling at the level of protein translation 
through riboswitches, which are structure-dependent regulators located in the 5’ or 
3’ untranslated region of mRNA (Nelson et al., 2013). Studies have shown that two c-
di-AMP molecules can bind to the ydaO riboswitch motif, leading to global 
conformational changes in the mRNA structure to form terminators (Nelson et al., 
2013). ydaO riboswitches control a broad range of gene expression, including genes 
encoding c-di-AMP synthases CdaA and DisA, and genes for cell wall metabolism, 
amino acid and ion transport, amino acid transport, and other signal transduction 
pathways (Barrick et al., 2004; Block et al., 2010). These reports provide further 
evidence that c-di-AMP is an important molecule in cell signaling. 
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1.2.2.2. c-di-AMP regulates enzyme activity by directly binding to the protein. 
In addition to regulating gene expression via binding to specific mRNAs, c-di-
AMP can also bind directly to some proteins, and control their activities via 
allosteric regulation (Corrigan and Gründling, 2013; Corrigan et al., 2013). Several c-
di-AMP receptors have been identified by protein pull-down assays (Corrigan et al., 
2013). Interestingly, most of them regulate transmembrane cation transport. The 
most conserved c-di-AMP synthases and phosphodiesterases are membrane 
proteins or membrane associated suggesting that like many signaling pathways c-di-
AMP transduces or responds to environmental changes leading to improved cellular 
fitness.  
1.2.3. Pathways regulated by c-di-AMP 
1.2.3.1. c-di-AMP is essential for bacterial growth. 
Both c-di-AMP depletion and accumulation are toxic for bacteria. Deletion of 
the genes encoding c-di-AMP synthase in the genome is fatal for bacilli (Luo and 
Helmann, 2012; Mehne et al., 2013). Intracellular c-di-AMP accumulation also 
inhibits growth, and causes aberrant small and curled morphologies (Bai et al., 
2013; Luo and Helmann, 2012; Mehne et al., 2013; Smith et al., 2012). These 
observations suggest maintaining c-di-AMP in a certain level is important for 
bacteria growth and fitness. 
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1.2.3.2. c-di-AMP signals DNA damage. 
c-di-AMP, together with c-di-AMP synthase DisA, have been shown to report 
on DNA damage in B. subtilis (Oppenheimer-Shaanan et al., 2011a). B. subtilis DisA 
scans the chromosomal DNA for double-stranded breaks and synthesize c-di-AMP 
(Oppenheimer-Shaanan et al., 2011a). The DNA lesions can stop DisA scanning and 
downregulate DiaA activity, which leads to decreased c-di-AMP levels in B. subtilis 
(Oppenheimer-Shaanan et al., 2011a). 
1.2.3.3. c-di-AMP regulates potassium homeostasis. 
In S. aureus and B. subtilis, c-di-AMP directly interacts with proteins involved 
in K+ transport, including cation proton antiporter CpaA, K+ transporter gating 
component KtrA, and KdpD in a K+ response module (Corrigan et al., 2013; Kim et 
al., 2015). c-di-AMP controls the translation of K+ transporter KtrAB by ydaO 
riboswitch (Kim et al., 2015; Nelson et al., 2013; Ren and Patel, 2014). Moreover, 
binding of c-di-AMP to KtrA inhibits K+ uptake (Kim et al., 2015). These data 
suggests c-di-AMP plays an important role in osmotic stress response (Corrigan et 
al., 2013). 
1.2.3.4. c-di-AMP regulates cell wall biosynthesis. 
In several Gram-positive organisms, increased intracellular c-di-AMP levels 
can make bacteria resistant to cell wall stress (Luo and Helmann, 2012; Smith et al., 
2012; Witte et al., 2013). In S. coelicolor, c-di-AMP can down regulate the expression 
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of cell wall hydrolase RpfA (Resuscitation Promoting Factor A) (Commichau et al., 
2015). In an S. aureus lipoteichoic acid (LTA)-deficient strain, increased cellular c-di-
AMP levels upregulated the amount of highly cross-linked peptidoglycan in the cell 
wall, which suggested that increased c-di-AMP levels may help strengthen the cell 
wall to protect bacteria against cell wall stress (Corrigan et al., 2011).  
1.2.3.5. c-di-AMP regulates biofilm formation. 
Several groups have reported that c-di-AMP can regulate biofilm formation 
(Gundlach et al., 2016; Peng et al., 2016). However, by knocking out different genes 
in different organisms led to varying biofilm phenotypes. A comparison of these 
studies is complicated by the observation that the different groups used different 
methods to test biofilm formation. In the experience of our research group the type 
of biofilm assay employed can often lead to substantially different conclusions about 
the ability to form biofilms. 
For instance, Peng et al. knocked out a DHH/DHHA1 c-di-AMP 
phosphodiesterase protein PdeA in Streptococcus mutans, and measured biofilm 
formation by a crystal violet assay (Peng et al., 2016). Peng et al. found that 
increased c-di-AMP promotes biofilm formation by upregulating the expression of 
glucan synthase GtfB (Peng et al., 2016). However, when Gundlach et al. knocked out 
c-di-AMP phosphodiesterases GdpP and PgpH in Bacillus subtilis, and tested biofilm 
formation by complex colony formation assays their results showed that 
upregulating c-di-AMP levels could activate transcription factor SinR to inhibit B. 
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subtilis biofilm formation (Gundlach et al., 2016). These observations suggest that c-
di-AMP may play different or more complex roles in different organisms in response 
to different stimuli. 
1.2.4. c-di-AMP is involved in antibiotic resistance. 
Increased intracellular c-di-AMP levels in bacteria have also been associated 
with increased tolerance to some antibiotics, including lysostaphin, oxacillin and 
penicillin G (Corrigan et al., 2011; Luo and Helmann, 2012; Smith et al., 2012). As 
mentioned above, c-di-AMP accumulation can upregulate highly cross-linked 
peptidoglycan to strengthen the cell wall (Corrigan et al., 2011). One of the reasons 
that increased c-di-AMP levels can protect bacteria from antibiotics targeting cell 
wall and cell membrane is that c-di-AMP regulates some aspects of cell wall 
biosynthesis and structure.  
1.3. c-di-AMP is a putative second messenger in enterococci. 
Although c-di-AMP has been identified in several Gram-positive bacteria, the 
cyclic dinucleotide signaling pathway and its potential role in signal transduction 
had not been characterized in the important clinical pathogen enterococci. 
1.3.1. Multidrug-resistant enterococci are rising. 
Enterococci are facultative anaerobic Gram-positive bacteria and are the 
cause of multiple human infections including endocarditis, bacteremia, nervous 
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system infections and urinary tract infections (Arias et al., 2011; Byappanahalli et al., 
2012; Wang et al., 2014). Since enterococci can acquire antibiotic resistant cassette 
from other Gram-positive pathogens by conjugation and can accumulate mutations 
for novel antibiotics resistance, multidrug-resistant (MDR) enterococci emerged 
rapidly in decades  (HICPAC, 1995; Rice et al., 1995). 
Among MDR enterococcus, vancomycin-resistant enterococci (VRE) is a 
serious public health threat that is resistant to almost all antibiotics clinically 
available (Arias and Murray, 2012). VRE infections usually affect critically ill and 
immunocompromised patients with increased prevalence in healthcare-associated 
infections (9,820 in 2000 to 20,000 in 2013 in the United States) and cause 1,300 
deaths in the United States each year (CDC, 2013). The cyclic lipopeptide 
daptomycin (DAP) is frequently used as a drug of last resort against recalcitrant VRE 
infections (Arias and Murray, 2012). 
1.3.2. Daptomycin is an efficacious antibiotic to treat vancomycin-resistant 
enterococci. 
Daptomycin (DAP) is a cyclic lipopeptide antibiotic produced by 
Streptomyces roseosporus during fermentation (Figure 1.3) (Arias et al., 2011). DAP 
is an efficacious antibiotic not only for VRE but also for other MDR pathogens such 
as methicillin-resistant S. aureus (MRSA) (Purrello et al., 2016). 
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Figure 1.3 Structure of daptomycin. Figure is produced by Chemdraw Professional.  
 
Several studies have been performed for the mechanism of DAP action (Jung 
et al., 2004; Müller et al., 2016; Robbel and Marahiel, 2010). The antibacterial 
activity of DAP depends highly on the concentration of Ca2+ (Hodinka et al., 1987; 
Jung et al., 2004). Ca2+ can induce DAP monomers to form micelles to approach cell 
membranes (Jung et al., 2004). DAP micelles than disassociate, and DAP inserts into 
the cell membrane in a phosphatidylglycerol-dependent manner (Jung et al., 2004). 
The insertion can interrupt cell wall synthesis and cause cation leakage, which 
results in cell death (Jung et al., 2004; Müller et al., 2016; Pogliano et al., 2012). 
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1.3.3. Mutations identified in DAP-resistant VRE showed a potential 
relationship between the LiaFSR cell membrane stress signaling pathway 
and c-di-AMP levels. 
Although DAP is effective against VRE, widespread clinical applications of 
DAP select for DAP resistance (Arias et al., 2011). In a previous study, Miller et al. 
used quantitative experimental evolution of a polymorphic population of 
Enterococcus faecalis S613 (hereafter referred to as: Efc S613) to identify common 
evolutionary trajectories leading to DAP resistance (Miller et al., 2013). All the initial 
mutations associated with resistance appeared directly within the liaFSR pathway 
including liaF and liaR (Miller et al., 2013; Palmer et al., 2011). LiaFSR is a three-
component membrane stress response regulon (Figure 1.4) (Wolf et al., 2010) that 
includes a transmembrane histidine kinase (LiaS) that is predicted to activate its 
cognate response regulator (LiaR) by phosphorylation in response to cell envelope 
stress (Schrecke et al., 2013). Upon activation, LiaR regulates downstream genes by 
binding DNA in a sequence specific manner including the liaFSR and liaXYZ operons 
(Davlieva et al., 2015a; Miller et al., 2013; Schrecke et al., 2013). Studies in B. subtilis 
have suggested that LiaF is an inhibitor of LiaS that attenuates signal response 
(Schrecke et al., 2013; Wolf et al., 2010).  
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Figure 1.4 LiaFSR pathway in enterococci. Cell envelope stress can active LiaS. LiaS 
then activates LiaR by phosphorylation, which leads to LiaR dimerization. LiaR dimers 
can regulate downstream gene expressions. LiaF can inhibit LiaS activity. (Davlieva et 
al., 2015b; Miller et al., 2013; Schrecke et al., 2013; Wolf et al., 2010) 
 
After an initial set of mutations within the LiaFSR pathway, a second group of 
genes showed clear indications of being important to adaptation to DAP and 
included cls (encoding a cardiolipin synthase) and gdpP.  
In addition to gdpP, I was able to identify potential homologs to a c-di-AMP 
synthase A (CdaA) and another cyclic-dinucleotide phosphodiesterase PgpH in the E. 
faecalis genome (ADDP01000030.1) (Huynh et al., 2015; Mehne et al., 2013). Thus, I 
postulated that if yybT was indeed a gdpP homolog, the c-di-AMP signaling pathway 
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may be important in enterococci and may influence different processes including 
the adaptive response to antimicrobial peptides like DAP. Interestingly, DAP-
resistant strains containing gdpPI440S were found in association with mutations in 
the LiaFSR system such as liaRD191N, suggesting a potential epistatic link to the 
LiaFSR regulon (Miller et al., 2013). Although gdpPI440S has not been observed in 
clinical isolates, the possibility that it was a phosphodiesterase provided the first 
indication that there might be a relationship between the LiaFSR pathway, cyclic 
dinucleotide signaling and DAP resistance.  
1.4. Goals of this project 
It is challenging to develop effective clinical therapies against enterococci 
since they rapidly accumulate mutations to acquire resistance against most 
antibiotics (Arias et al., 2011). Our ability to develop new antibiotics or new 
therapeutic approaches to infections by enterococci would greatly benefit from a 
better understanding of how they respond to antibiotic stress. Based upon the 
earlier work of Miller et al., that c-di-AMP signaling was not only present in 
enterococci but was important to their stress response including those related to 
the membrane damage response pathway LiaFSR (Miller et al., 2013). 
In this study, I show for the first time that c-di-AMP is a second messenger in 
enterococci. Using in vitro enzymatic activity assays, I show that E. faecalis GdpP (Efc 
GdpP) is a bone fide c-di-AMP specific phosphodiesterase. The GdpPI440S substitution 
identified during selection to DAP has reduced activity both in vitro and in vivo and 
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leads to accumulation of c-di-AMP. I also show my structural studies of Efc GdpP and 
E. faecium GdpP (Efm GdpP). As there is no structure of full-length GdpP protein, 
GdpP protein structure solved by crystallography will reveal the putative substrate 
and inhibitor binding sites and how the five domains in GdpP regulate each other.  
Additionally, I provide data that link the LiaFSR and LiaXYZ pathways and changes 
in c-di-AMP levels. I show that a putative c-di-AMP phosphodiesterase XpaC is under 
direct LiaR regulation. Taken together, my data suggest that the membrane stress 
response of enterococci via GdpP or LiaFSR signaling, affects c-di-AMP levels. The 
changes in c-di-AMP may have important physiological implications for the adaptive 
response to antibiotics in enterococci. Results obtained from this project improve 
our understanding of ways the mutations in the genome help enterococci resist DAP. 
It also provides new possible targets for antibacterial therapies of DAP-resistant 
Gram-positive pathogens. 
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Chapter 2 
Materials and Methods 
2.1. Enterococci strains and growth media 
Enterococci strains used in this study are listed in Table 2.1. E. faecalis (Efc) 
OG1RF harboring pMSP3535 and recombinant plasmids were grown in brain heart 
infusion (BHI) supplied with 10 µg/ml erythromycin and nisin as described in 
(Bryan et al., 2000). Other Efc strains were grown in LBHI broth (80% lysogeny 
broth (LB) and 20% brain heart infusion (BHI)) as described in (Miller et al., 2013). 
E. faecium (Efm) HOU503 was grown in LBHI. Other E. faecium strains were grown 
in BHI. When DAP was added, 50 mg/L CaCl2 was supplied to the medium (Miller et 
al., 2013).  
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Table 2.1 Summary of enterococci strains used in this study. 
Strains Genotype or description Reference or 
source 
E. faecalis strains 
S613 Wild type clinical VREa strain (Arias et al., 2011; 
Reyes et al., 2015) 
OG1RF Wild type laboratory vancomycin-
susceptible strain 
(Arias et al., 2011; 
Reyes et al., 2015) 
R712 Clinical daptomycin-resistant strain derived 
from S613. liaFΔI177 clsΔK61 gdpDΔI170 
(Arias et al., 2011; 
Reyes et al., 2015) 
TDR7 Experimental daptomycin-resistant strain 
derived from S813. liaXV289fs clsR217Q 
(Miller et al., 2013) 
S613_D17C9b liaFΔI177, prgUG105G, EFE19809.1/19808.1 
intergenic 34bp deletion 
This study 
S613_D18A10b liaFΔI177, xpaC1-163fs, dacAE554K, prgUN103N, 
EFE19809.1/19808.1 34bp intergenic 
deletion, GT in EFE19513.1/ EFE19514.1 
intergenic region 
This study 
OG1RF_ΔliaR ΔliaR (Reyes et al., 2015) 
OG1RF_ΔliaR::liaR OG1RF_ΔliaR with liaR complementation in 
cis 
(Reyes et al., 2015) 
OG1RF_liaX1-289 OG1RF with a stop codon inserted after LiaX 
residue 289 
Arias Lab 
OG1RF_ΔliaX ΔliaX Arias Lab 
OG1RF_ΔliaY ΔliaY Arias Lab 
OG1RF_ΔliaZ ΔliaZ Arias Lab 
OG1RF_ΔliaYZ ΔliaYZ Arias Lab 
OG1RF:: 
pMSP3535::gdpP 
pMSP3535::gdpP-Efc  This study 
OG1RF:: 
pMSP3535::gdpPI440S 
pMSP3535::gdpPI440S-Efc This study 
OG1RF:: pMSP3535 pMSP3535 This study 
E. faecium strains 
HOU503 Clinical daptomycin-tolerant VRE strain with 
liaRW37C and liaST120A. 
(Panesso et al., 
2015) 
HOU503F HOU503 fusidic acid-resistant derivative (Panesso et al., 
2015) 
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aVRE: vancomycin-resistant enterococci. 
bPlease see Table 4.1 for details of Efc S613_D17C9 and Efc S613_D18A10. 
 
2.2. Measurement of intracellular c-di-AMP by competitive ELISA 
A c-di-AMP competitive enzyme-linked immunosorbent assay (ELISA) 
protocols were optimized from Underwood et al., 2014 (Underwood et al., 2014) to 
measure the intracellular c-di-AMP concentrations in Efc and Efm.  
To prepare samples for c-di-AMP measurement, enterococcus cells were 
grown to late exponential phase (OD600~1.0 for E. faecalis, and OD600~1.2 for E. 
faecium). Cell pellets from 45 mL or 90 mL cultures were washed by 5 mL PBS 3 
times, and re-suspended in 0.5 mL 50 mM Tris-HCl pH 8.0. Cells were opened by 
sonication on ice for 1 min total time (10 s on and 3 min off at output 6/50% duty 
cycle in every cycle). Samples were boiled at 95°C for 5 min. Supernatants were 
HOU503F_ΔliaR ΔliaR (Panesso et al., 
2015) 
HOU503F_ΔliaR::liaR HOU503F_ΔliaR with liaR complementation 
in cis 
(Panesso et al., 
2015) 
R497F Fusidic acid-resistant derivative of the 
clinical daptomycin-resistant vancomycin-
susceptible E. faecium strain R497 with 
liaRW37C, liaST120A, and clsins110 
(Panesso et al., 
2015) 
R497F_ΔliaR ΔliaR (Panesso et al., 
2015) 
R497F_ΔliaR::liaR F497F_ΔliaR with liaR complementation in 
cis 
(Panesso et al., 
2015) 
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collected after centrifugation at 12,000g for 15 min. Samples were used immediately 
for the following steps. 
Streptococcus pneumoniae CabP (Spn CabP) was purified as described Bai et 
al., 2014 (Bai et al., 2014). Nunc MaxiSorp Immuno 96-well microplate (Fisher 
Scientific) was coated with 100 µL/well coating buffer containing 200 µg/mL Spn 
CabP at 4°C for 17-18 hr. Plates were washed by PBST (PBS with 0.05% (v/v) 
Tween 20) three times, and then blocked by the addition 100 µL/well 1% (w/v) 
bovine serum albumin (BSA) in PBS for 1 h at room temperature. Plates were 
washed again with PBST three times. 2'-[Biotin]-AHC-c-diAMP (Biolog B106) was 
added to samples to 25 nM final concentration. 100 µL of each sample was added to 
the plate, and incubated at room temperature for 3 h. The plate was washed by 
PBST three times. HRP-Conjugated Streptavidin (ThermoFisher) was diluted 
1:10,000 in PBS, and 100 µL was added to each well. The plate was incubated in the 
dark at room temperature for 1.5 h, and was washed with PBST three times. 100 
µL/well substrate buffer (as described in (Underwood et al., 2014)) was then added 
to the plate. The plate was incubated in the dark for 1h, and 2 M H2SO4 was added to 
stop the reaction. The absorbance at 492 nm was measured by plate reader 
(BioRad). The absorbance at 630 nm was used as baseline absorbance. Coating 
buffer and substrate buffer was prepared as described by Underwood et al. 
(Underwood et al., 2014). A H2O2 final concentration of 0.2% was used in the 
substrate buffer.  
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2.3. Plasmid construction for protein overexpression 
The Efc gdpP and subdomains were amplified by PCR from Efc S613 using 
specific primers (Table 2.2) with PfuUltraII DNA Polymerase. Mutations Y212A, 
D419A, I440S, D499A in Efc GdpP were generated by site directed mutagenesis 
(Table 2.2). The Efm gdpP and subdomains were amplified from Efm R494 by PCR 
using specific primer listed in Table 2.3. The xpaC genes were amplified from Efc 
S613, Efm HOU503 and MRSA 131 by PCR using specific primers listed in Table 2.4. 
PCR products were digested by appropriate restriction endonucleases and 
cloned into pET-28a (Novagen) for expression in E. coli BL21, or into pMSP3535 
(Bryan et al., 2000) for expression in Efc OG1RF.  
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Table 2.2 Primers used in this study for molecular cloning of Efc gdpP. 
Primer Sequence 
Efc GdpP with N-His tag forward 
primer for pET-28a 
TTCTCCCATGGATGCATCATCATCACCATCACGAAA
ACTTGTATTTCCAGGGGATGCAAAAGAAGAGAATT
CAA 
Efc GdpP with N-His tag reverse 
primer for pET-28a 
TTCTCAAGCTTTCACTCCTGTTCATACATTTC 
Efc GdpP with C-His tag forward 
primer for pET-28a 
TTCTCCCATGGATGCAAAAGAAGAGAATTCAA 
Efc GdpP with C-His tag reverse 
primer for pET-28a 
TTCTCAAGCTTTCAATGGTGATGATGATGATGTTCG
TTCAAATAGAACTGCCCCTCCTGTTCATACATTTC 
Efc GdpP167-300 with N-His tag 
forward primer 
TTCTCCCATGGATGCATCATCATCACCATCACGAAA
ACTTGTATTTCCAGGGGAAAGTCGAAATGCAAACG
GCTATT 
Efc GdpP167-300 with N-His tag 
reverse primer 
TTCTCAAGCTTTCAATCTTTGGCTTCTTTTAC 
Efc GdpP82-159 with N-His tag 
forward primer 
TTCTCCCATGGATGCATCATCATCACCATCACGAAA
ACTTGTATTTCCAGGGGGTACCTGTGGGAATTATT
ACG  
Efc GdpP82-159 with N-His tag reverse 
primer 
TTCTCAAGCTTTCATTTAGTGATATCTTCAAAAGT 
Efc GdpP332-658 with N-His tag 
forward primer 
TTCTCCCATGGATGCATCATCATCACCATCACGAAA
ACTTGTATTTCCAGGGGATTATTGCGGAATCTGCT
GAC 
Efc GdpP56-658 with N-His tag 
forward primer 
TTCTCCCATGGATGCATCATCATCACCATCACGAAA
ACTTGTATTTCCAGGGGGTAGAAATTACAAACGTA
GAA 
Efc GdpP309-658 forward primer for 
pET-28a 
TTCTCCCATGGATGCATCATCATCACCATCACGAAA
ACTTGTATTTCCAGGGGATGCAAAAGAAGAGAATT
CAA 
Efc GdpP forward primer for 
pMSP3535 
TTCTCACTAGTATTGGAGGCAAAAAAATGCATCAT
CATCACCATCACGAAAACTTGTATTTCCAGGGACA
AAAGAAGAGAATTCAAAAAAACG 
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Efc GdpP reverse primer for 
pMSP3535 
TTCTCCTCGAGTCACTCCTGTTCATACATTTCATT 
GST-GdpP forward primer TTCTTGGATCCATGCAAAAGAAGAGAATC 
GST-GdpP reverse primer TTCTTCTCGAGTCACTCCTGTTCATACATT 
Efc GdpP Y212A mutagenesis 
forward primer 
GGATGGACCAAGCCAAAGTTTTTTA 
Efc GdpP Y212A mutagenesis 
reverse primer 
TAAAAAACTTTGGCTTGGTCCATCC 
Efc GdpP D419A mutagenesis 
forward primer 
GTAGCTTACCATAAACCGTCTCTAT 
Efc GdpP D419A mutagenesis 
reverse primer 
ATAGAGACGGTTTATGGTAAGCTAC 
Efc GdpP I440S mutagenesis 
forward primer 
AAGTGGTAAGCATTGATCACCATCG 
Efc GdpP I440S mutagenesis reverse 
primer 
CGATGGTGATCAATGCTTACCACTT 
Efc GdpP D499A mutagenesis 
forward primer 
GAATTGTGGTTGCTACGAAAAGTTT 
Efc GdpP D499A mutagenesis 
reverse primer 
AAACTTTTCGTAGCAACCACAATTC 
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Table 2.3 Primers used in this study for molecular cloning of Efm gdpP. 
Primer Sequence 
Efm GdpP with N-His tag forward 
primer for pET-28a 
TTCTCCCATGGATGCATCATCATCACCATCACGAAA
ACTTGTATTTCCAGGGGGAAAATAAAAACAATCAT
TTATCC 
Efm GdpP with N-His tag reverse 
primer for pET-28a 
TTCTCGAATTCTTACTCCTTATC ATATATTTG 
Efm GdpP338-657 with N-His tag 
forward primer for pET-28a 
TTCTCCCATGGATGCATCATCATCACCATCACGAAA
ACTTGTATTTCCAGGGGGTGTTTATCAT 
GGGGCACAAG 
Efm GdpP137-298 with N-His tag 
forward primer for pET-28a 
TTCTCCCATGGATGCATCATCATCACCATCACGAAA
ACTTGTATTTCCAGGGGGATAAAACATTTCAGTTT
GATATG 
Efm GdpP137-298 with N-His tag 
reverse primer for pET-28a 
TTCTCGAATTCTTATTTTACCTCTTTCACGACAAC 
Efm GdpP83-657 with N-His tag 
reverse primer for pET-28a 
TTCTCCCATGGATGCATCATCATCACCATCACGAAA
ACTTGTATTTCCAGGGGCCTGTAGGAGTGATTGC 
Efm GdpP338-500 with N-His tag 
reverse primer for pET-28a 
TTCTCGAATTCTTAATTTGTATCTACAACCATCCCTG
C 
Efm GdpP83-167 with N-His tag 
reverse primer for pET-28a 
TTCTCGAATTCTTAGTTAAAACTCCATCAGACG 
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Table 2.4 Primers used in this study for molecular cloning of xpaC. 
Primer Sequence 
Efc S613 & TX1467 XpaC with N-
terminal His-tag forward primer for 
pET-28a 
TTCTCGAATTCATGCATCATCATCACCATCACAACA
AATTAAATACAAAA 
Efc S613 & TX1467 XpaC no-tag 
reverse primer for pET-28a 
TTCTCAAGCTTTTATTGCTGGTCTTCGTTTAC 
Efc S613 & TX1467 XpaC forward 
primer for pET-28a N-terminal His-
tag 
TTCTCGAATTCAACAAATTAAATACAAAATTAC 
Efc S613 & TX1467 XpaC with C-
terminal His-tag forward primer for 
pET-28a 
TTCTCCCATGGATGAACAAATTAAATACAAAATTAC
TG 
Efc S613 & TX1467 XpaC with C-
terminal His-tag reverse primer for 
pET-28a 
TTCTCAAGCTTTTAGTGATGGTGATGATGATGTTG
CTGGTCTTCGTTTACTTGAGG 
Efc S613 XpaCK163fs with C-terminal 
His-tag reverse primer for pET-28a 
TTCTCAAGCTTCTAGTGATGGTGATGATGATGATTT
TTCATACGTTTGTTTTTTAC 
Efc S613 XpaC no-tag forward 
primer for pMSP3535 
TTCTCACTAGTATAGGAGGAACTATATAAATGAAC
AAATTAAATACAAAATTACTG 
Efc S613 XpaC unremovable N-
terminal His-tag forward primer for 
pMSP3535 
TTCTCACTAGTATAGGAGGAACTATATAAATGCAT
CATCATCACCATCACAACAAATTAAATACAAAATTA
CTG 
Efc S613 XpaC removable N-
terminal His-tag forward primer for 
pMSP3535 
TCTCACTAGTATAGGAGGAACTATATAAATGCATC
ATCATCACCATCACGAAAACTTGTATTTCCAGGGA
AACAAATTAAATACAAAATTACTG 
Efc S613 XpaC no-tag reverse primer 
for pMSP3535 
TTCTCCTCGAGTTATTGCTGGTCTTCGTTTACTTG 
Efc S613 XpaC unremovable C-
terminal His-tag reverse primer for 
pMSP3535 
TTCTCCTCGAGTTAGTGATGGTGATGATGATGTTG
CTGGTCTTCGTTTACTTG 
Efc S613 XpaC removable C-terminal 
His-tag reverse primer for 
TTCTCCTCGAGTTAGTGATGGTGATGATGATGTCC
CTGGAAATACAAGTTTTCTTGCTGGTCTTCGTTTAC
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pMSP3535 TTG 
Efc S613 XpaC1-163 no-tag reverse 
primer for pMSP3535 
TTCTCCTCGAGCTAATTTTTCATACGTTTGTTTTTTA
C 
Efc S613 XpaC1-163 unremovable C-
terminal His-tag reverse primer for 
pMSP3535 
TTCTCCTCGAGTTAGTGATGGTGATGATGATGATT
TTTCATACGTTTGTTTTTTAC 
Efc S613 XpaC1-163 removable C-
terminal His-tag reverse primer for 
pMSP3535 
TTCTCCTCGAGTTAGTGATGGTGATGATGATGTCC
CTGGAAATACAAGTTTTCATTTTTCATACGTTTGTTT
TTTAC 
Efm HOU503 XpaC with removable 
N-terminal His-tag forward primer 
for pET-28a 
TTCTCCCATGGATGCATCATCATCACCATCACGAAA
ACTTGTATTTCCAGGGGATAAAACGAAATTGGCCG
TGGC 
Efm HOU503 XpaC no-tag reverse 
primer for pET-28a 
TTCTCGAATTCTTAATCCTTTTGTTCTGGTTC 
Efm HOU503 XpaC no-tag forward 
primer for pET-28a 
TTCTCCCATGGATGATAAAACGAAATTGGCCGTGG
C 
Efm HOU503 XpaC with C-terminal 
His-tag reverse primer for pET-28a 
TTCTCGAATTCTTAGTGATGGTGATGATGATGATCC
TTTTGTTCTGGTTCATA 
MRSA 131 XpaC with removable N-
terminal His-tag forward primer for 
pET-28a 
TTCTCCCATGGATGCATCATCATCACCATCACGAAA
ACTTGTATTTCCAGGGGACAGTGAGATATAATATT
TCTCA 
MRSA 131 XpaC no-tag reverse 
primer for pET-28a 
TTCTCAAGCTTTCAATCTTGATGATGTTTTTGATGT
AAC 
MRSA 131 XpaC no-tag forward 
primer for pET-28a 
TTCTCCCATGGATGACAGTGAGATATAATATTTCTC 
MRSA 131 XpaC with unremovable 
C-terminal His-tag reverse primer 
for pET-28a 
TTCTCAAGCTTTCAGTGATGGTGATGATGATGATCT
TGATGATGTTTTTGATGTAAC 
MRSA 131 XpaC with unremovable 
N-terminal His-tag forward primer 
for pET-28a 
TTCTCCCATGGATGCATCATCATCACCATCACACAG
TGAGATATAATATTTCTCA 
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2.4. Expression and purification of E. faecalis GdpP  
Overnight cultures of E. coli BL21 carrying the Efc GdpP expression vector 
pET28a-Efc_GdpP was diluted 1:100 in 8L 2xYT medium supplemented with 50 
mg/L kanamycin. To express protein for crystallization, additional 5 µM heme 
(Sigma) was added to the cultures. Cultures were shaken at 37°C until the OD600 
reached 0.6~0.7. 0.5 mM IPTG was then added to induce protein expression. 
Cultures were shaken at 16°C for 20 h before being harvested by centrifugation. 
Cells were resuspended by a Ni-NTA buffer A (50 mM Tris pH 7.4, 20 mM Imidazole, 
500 mM NaCl, 10 mM -mercaptoethanol, 0.2 mM PMSF, 5% Glycerol (v/v)), and 
opened by sonication on ice with 3 cycles of 2 min on and 3 min off at output 6/50% 
duty cycle. Supernatants were collected by centrifugation at 24,000 rpm for 1 h at 
4°C. The protein was purified initially with a gravity Ni-NTA column, and was step 
eluted by Ni-NTA buffer B (50 mM Tris pH 7.4, 200 mM Imidazole, 440 mM NaCl, 9 
mM β-mercaptoethanol, 0.2 mM PMSF, 5% Glycerol (v/v)). The fractions containing 
target protein were collected and dialyzed overnight at 4°C against gel filtration 
buffer (25 mM CHES pH 8.6, 200 mM NaCl). Protein was subsequently concentrated 
and further purified on a HiLoad 16/60 Superdex 200 gel filtration column. 
Fractions containing target protein were collected. Fresh protein should be used for 
the following experiments as storage at -80°C reduces activity.  
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2.5. Product analysis of GdpP reactions by HPLC  
For ATPase activity, 10 µM protein and 100 µM ATP was incubated at 28˚C 
for 2 h in a reaction buffer containing 40 mM Tris pH 7.5 and 10 mM MgCl2. For 
phosphodiesterase activity, 10 µM protein was incubated with 100 µM c-di-AMP or 
c-di-GMP at 28˚C for 2 h in a reaction buffer containing 100 mM Tris pH 8.3, 20 mM 
KCl, and 0.5 mM MnCl2. 1mM ppGpp was added to the reaction buffer in 
experiments to estimate ppGpp inhibition of GdpP phosphodiesterase activity. 
Reactions were stopped and protein precipitated by addition of trifluoroacetic acid 
(TFA) to 1% (v/v) final concentration and incubated on ice for 15 min. Precipitants 
were removed by centrifugation. A total of 10 µL nucleotide standards or samples 
were injected into RP C-18 column (Hamilton #79674), and eluted with a gradient 
of 0 to 100% (Buffer A: 0.1M KH2PO4, 4 mM tetrabutylammonium bromide, pH 6.0. 
Buffer B: 60% Buffer A, 40% methanol, pH 5.5.). 
2.6. Kinetics Measurement of the phosphodiesterase activity 
The protocols were optimized from the coralyne fluorescence turn-on assay 
described in (Zhou et al., 2014) to measure the phosphodiesterase kinetics of Efc 
GdpP309-658. 2.5 µM Efc GdpP309-658 was incubated with 0-1750 µM c-di-AMP (Biolog) 
at 37 ˚C in thermal cycler. The reaction buffer contains 50mM CHES pH9.2, 20mM 
KCl, 0.5 mM MnCl2, and 1 mM fluorinated octyl maltoside (Anatrace). The reactions 
were stopped after incubated for 0, 2 min, 4 min, and 6 min by heated up to 95 ˚C for 
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3 min. Precipitated proteins were removed by 96-well filter plate (EconoSpin). c-di-
AMP concentrations were measured by mixed with coralyne buffer to a final 
condition contained 100 mM coralyne (Sigma), 50 mM CHES pH9.2, and 3 mM KI. 
Fluorescence intensities (ex. 420 nm, em. 475 nm) were measured by plate reader 
(BioRad).  
2.7. Expression Efc GdpP and Efc GdpPI440S in E. faecalis OG1RF 
The Efc OG1RF strains with recombinant plasmids were grown in BHI with 
10 µg/ml erythromycin. The overnight cultures of Efc OG1RF with recombinant 
plasmids were diluted 1:100 to BHI with 10 µg/ml erythromycin on the second day, 
and 20 ng/ml nisin was added when the OD600 was ~0.5. Cultures were incubated at 
37°C shaken at 225 rpm overnight. On the third day, the overnight cultures were 
then re-diluted into BHI with 10 µg/ml erythromycin, 20 ng/ml nisin. Cells were 
harvested after their OD600 reaching 1.5 (late exponential phase of Efc OG1RF 
strains with pMSP3535 plasmids) for c-di-AMP measurements. 
2.8. Kinetics measurement of the ATPase activity 
The steady-state kinetic parameters were determined using EnzChek® 
Phosphate Assay Kit (Life Technologies) by measuring the release of inorganic 
phosphate (Pi) hydrolyzed from ATP. The reactions were set up in 96-well plate, 
and were monitored by Bio-Rad plate reader.  
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2.9. Structural modeling 
The structural model of Efc GdpP DHH-DHHA1 domain was built using 
Phyre2 server. The Mn+2 ions positions were predicted by alignment to 
Mycobacterium tuberculosis phosphodiesterase Rv2837c (Protein Data Bank entry 
5CET) (He et al., 2015). 
2.10. Expression and Purification of Efc GST-GdpP 
    Overnight cultures of E. coli BL21 with recombinant plasmid pET28a-
Efc_GST-GdpP was diluted 1:100 in 8L 2xYT with 100 mg/L ampicillin. 0.5 mM IPTG 
was added when the culture reached an OD600 of ~0.7-0.8. Culture was shaken at 
16°C for 20 h before harvesting by centrifugation.  
Cells were resuspended in Lysis Buffer A (50mM Tris pH8.0, 150 mM NaCl, 
5% Glycerol (v/v)). Cells were opened by sonication. Supernatant was collected 
after centrifugation at 24,000 rpm for 1 h at 4°C. The protein was purified with 5ml 
glutathione agarose (Thermo scientific #16100), and eluted by an Elution Buffer 
(50mM Tris pH 8.0, 150 mM NaCl, 10 mM reduced glutathione, 5% Glycerol (v/v)). 
The fractions containing GST-GdpP were collected and dialyzed at 4°C overnight 
against the Dialysis Buffer (50mM Tris pH8.0, 200mM NaCl). Unfrozen protein was 
used for the heme reconstitution assay. 
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2.11. Quantitative PCR 
RNA isolation and cDNA synthesis were performed as described in Miller et 
al., 2013 (Miller et al., 2013). Quantitative PCR was performed using B-R SYBR® 
Green SuperMix Kit (Quanta) and real-time thermal cycler (Bio Rad). Primers for 
qPCR are listed in Table 2.5.  
Table 2.5 Primers used in this study for quantitative PCR. 
Target gene Sequence 
Primers for Efc S613 and Efc OG1RF genes 
liaF 
Forward primer ATTGGCGTTTTACTTGTGGC 
Reverse primer ATCAACATAAACCAAACAGCCG 
liaR 
Forward primer AGTGTATCCGGCGATTGAAG 
Reverse primer TCTTATGCGTCACTTCAGGTTC 
liaY 
Forward primer TGATTGGCTAGGAATTGACCC 
Reverse primer AGAGAATGCCTGGAAATCCTG 
liaZ 
Forward primer GGGAAATGAACTTTGGCTTCTC 
Reverse primer TTTCGATAAATTGTGATCCGTAACG 
cdaA 
Forward primer TCAACCAGAAGTGCGAAGAG 
Reverse primer CCGTTTTGACATGTACTGAATGG 
cdaR 
Forward primer AGATGCCAAAGGTCAAGTCC 
Reverse primer GTGGCGTACCTGTCATACTAAC 
gdpP 
Forward primer GAGGCGATTAAAGAGTACCCAG 
Reverse primer CTTGTGAGATCGATAGAGACGG 
xpaC 
Forward primer GCTGTCGCTAGAGAATATGGC 
Reverse primer CAACTCACGATAATGGGCTTC 
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relA 
Forward primer GACTTGCTTCGTCAGTTCATC 
Reverse primer CCAAAAGGGAATCCAGTAGAGG  
relQ 
Forward primer CAGGACGTGTGAAACCAGTAG 
Reverse primer AGTGCGACTACCTGGTAAATG 
relA 
Forward primer GACTTGCTTCGTCAGTTCATC 
Reverse primer CCAAAAGGGAATCCAGTAGAGG 
relQ 
Forward primer CAGGACGTGTGAAACCAGTAG 
Reverse primer AGTGCGACTACCTGGTAAATG 
Primers for Efc S613 genes 
liaS 
Forward primer CAAGCACAACGAACAGAAACC 
Reverse primer CTTCTAGACTGATAGGACGCAAG 
liaX 
Forward primer TGGTGATGTGTCTATTTCCGC 
Reverse primer GATATTCCCATTTGCAGAGCTTG 
ghd2 
Forward primer AGCCAAGCAAGAACAGAAGC 
Reverse primer ATTGCGACATTCCCACTACC 
pgpH 
Forward primer TGCTGATACTTGTGAGGCTG 
Reverse primer TCTCTTTCATCGTTAACCCGC 
cspA 
Forward primer TGGAAACAGGTACAGTAAAATGG 
Reverse primer CGTCACCTTGGATAGCTGAG 
EFE19808.1 
Forward primer TTTCATTCCCTCGTGGCG 
Reverse primer AGAACATAAAGACGGTCCAGC 
perM 
Forward primer TCACATCGTTCAAGCCACC 
Reverse primer TTGAGCTTAGTCCCAGTTGC 
Primers for Efc OG1RF genes 
liaX 
Forward primer CTTCTAGACTGATAGGACGCAAG 
Reverse primer ACAAGCACAACGAACAGAAAC 
liaX Forward primer GACCTACTGTTGATTCGTTTGAAG 
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Reverse primer CAATTTCTGCGTTGACTTCGTC 
pgpH 
Forward primer GGCCATCTGAAATTCTGTCTTG 
Reverse primer TCCACAAACACGAGAAGCAG 
gdhA 
Forward primer GGTCCAAGTACAGATGTTCCAG 
Reverse primer GGCTTCCCCAGTATCCTAAAG 
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Chapter 3 
GdpP Modulates c-di-AMP Levels in 
Enterococci 
3.1. Introduction 
While c-di-AMP was detected in many Gram-positive bacteria, it had not been 
studied in enterococci. Since the Efc S613 genome (ADDP01000030.1) has potential 
homologs to c-di-AMP synthase CdaA and phosphodiesterases GdpP and PgpH, a 
role for c-di-AMP in enterococci seemed reasonable (Huynh et al., 2015; Mehne et al., 
2013). Additionally, as the adaptive mutant Efc gdpPI440S was identified in DAP-
resistant Efc strains via experimental evolution, Efc GdpP was a good candidate  to 
be a critical component of any cellular c-di-AMP signaling pathways (Miller et al., 
2013). 
In this chapter, I show that c-di-AMP is present in enterococci. Using in vitro 
and in vivo assays, I demonstrate that Efc GdpP is an c-di-AMP specific 
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phosphodiesterase and regulates intracellular c-di-AMP levels. I also show that the 
DAP adaptive mutation I440S strongly diminishes Efc GdpP phosphodiesterase 
activity and upregulates c-di-AMP levels, which suggests c-di-AMP accumulation 
may protect bacteria from cell wall stress. 
3.2. The nucleotide signaling molecule c-di-AMP is present at 
physiologically relevant levels in enterococci. 
As c-di-AMP signaling has not been previously identified in enterococci, it 
was essential to test whether c-di-AMP was present at levels consistent with being a 
second messenger in vivo.  
In order to measure c-di-AMP levels I optimized a c-di-AMP specific 
competitive enzyme-linked immunosorbent assay (ELISA) for detecting c-di-AMP 
(Underwood et al., 2014). The assay was initially developed and applied to E coli 
expressing  M. tuberculosis c-di-AMP synthase DisA and had to be refined for the 
measurement of c-di-AMP in enterococci (Underwood et al., 2014). I measured c-di-
AMP levels in Efc S613 and its DAP-resistant derivative Efc R712, a vancomycin-
resistant strain-pair isolated from the bloodstream of a patient before and after DAP 
treatment respectively. Additionally, I included a laboratory strain of E. faecalis (Efc 
OG1RF) (Table 3.1) (Arias et al., 2011; Bourgogne et al., 2008). Samples were 
collected at late exponential phase (OD600~1.0). As shown in Figure 3.1, Efc S613 
and Efc OG1RF strains produced c-di-AMP. The c-di-AMP level was 113±81 
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pM/OD600, and 112±47 pM/OD600 for Efc S613 and Efc OG1RF, respectively, at late 
exponential phase. 5In Efc R712 (DAP-resistant derivative of Efc S613), the c-di-
AMP level was 349±104 pM/OD600, more than 3-fold higher than Efc S613 (Table 3.1 
and Figure 3.1).  
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Table 3.1 Summary of enterococci strains in this study and their measured c-di-AMP concentrations and MICs to 
daptomycin. 
Strains Genotype or description 
Intracellular 
[c-di-AMP]a 
(pM/OD600) 
DAP MICsb 
(µg/ml) 
Reference or 
source 
E. faecalis strains 
S613 Wild type clinical VREc strain 113±81 0.5 (Arias et al., 2011; Reyes et al., 2015) 
OG1RF Wild type laboratory vancomycin-susceptible strain 112±47 2 
(Arias et al., 2011; 
Reyes et al., 2015) 
R712 Clinical daptomycin-resistant strain derived from S613. liaFΔI177 clsΔK61 gdpDΔI170 349±104 12 
(Arias et al., 2011; 
Reyes et al., 2015) 
TDR7 Experimental daptomycin-resistant strain derived from S813. liaXV289fs clsR217Q 268±97 12 
(Miller et al., 
2013) 
S613_D17C9d liaFΔI177, prgUG105G, EFE19809.1/19808.1 
intergenic 34bp deletion 735±118 3 This study 
S613_D18A10d liaFΔI177, xpaC1-163fs, dacAE554K, prgUN103N, 
EFE19809.1/19808.1 34bp intergenic deletion, 
GT in EFE19513.1/ EFE19514.1 intergenic 
region 
1493±61 3 This study 
OG1RF_liaX1-289 OG1RF with a stop codon inserted after LiaX residue 289 111±7 12 Arias Lab 
OG1RF_ΔliaX ΔliaX 101±7 12 Arias Lab 
OG1RF_ΔliaY ΔliaY 26±33 2 Arias Lab 
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Table continued. 
Strains Genotype or description 
Intracellular 
[c-di-AMP]a 
(pM/OD600) 
DAP MICsb 
(µg/ml) 
Reference or 
source 
OG1RF_ΔliaZ ΔliaZ 14±7 2 Arias Lab 
OG1RF_ΔliaYZ ΔliaYZ 64±12 2-3 Arias Lab 
OG1RF:: pMSP3535::gdpP pMSP3535::gdpP-Efc  115±9 0.5 This study 
OG1RF:: pMSP3535::gdpPI440S pMSP3535::gdpPI440S-Efc 152±3 0.5 This study 
OG1RF:: pMSP3535 pMSP3535 158±3 0.5 This study 
E. faecium strains 
HOU503 Clinical daptomycin-tolerant VRE strain with liaRW37C and liaST120A. 766±318 3 
(Panesso et al., 
2015) 
HOU503F HOU503 fusidic acid-resistant derivative 542±133 3 (Panesso et al., 2015) 
R497F 
Fusidic acid-resistant derivative of the clinical 
daptomycin-resistant vancomycin-susceptible 
E. faecium strain R497 with liaRW37C, liaST120A, 
and clsins110 
549±150 24 (Panesso et al., 2015) 
   
aErrors correspond to standard deviations among three individual measurements. 
bMIC: Minimum Inhibitory Concentration. The MICs were measured by Etest (bioMérieux) on MH (Mueller Hinton) agar. 
cVRE: vancomycin-resistant enterococci. 
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Figure 3.1 c-di-AMP is present in enterococci. Intracellular c-di-AMP concentrations were measured by an enzyme-linked 
immunosorbent assay (ELISA) (Underwood et al., 2014). c-di-AMP was detected in both of E. faecalis and E. faecium. Each c-di-
AMP measurement was made from at least three independent biological measurements. (See Table 3.1 for strain descriptions.) 
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To determine whether c-di-AMP signaling is present in other enterococci 
strains, a DAP-tolerant and vancomycin-resistant Efm clinical isolate HOU503 
(referred to as Efm HOU503 hereafter) and its fusidic acid-resistant derivative Efm 
HOU503F were tested (Table 3.1) (Panesso et al., 2015). The c-di-AMP level was 
766±318 pM/OD600 and 542±133 pM/OD600 for Efm HOU503 and Efm HOU503F at 
late exponential phase (OD600~1.2) (Table 3.1 and Figure 3.1) both significantly 
higher than those of E. faecalis. Interestingly, it has been reported that the c-di-AMP 
level in S. pneumoniae is ~ 25 pM/OD620 (Bai et al., 2013) and that c-di-AMP is 
present in cytoplasmic extracts from other Gram-positive bacteria. Using alternative 
methods to measure c-di-AMP, B. subtilis has ~1.7 µM/1 L culture (Oppenheimer-
Shaanan et al., 2011a) and 3.33±0.44 ng/mg bacterial dry weight in S. aureus 
(Corrigan et al., 2011). While c-di-AMP signaling molecules have been identified in a 
number of bacteria, the presence of c-di-AMP in E. faecalis and E. faecium had not 
been reported before and our results demonstrate that c-di-AMP is present in 
enterococci at levels to be a bone fide in vivo signal.  
3.3. E. faecalis GdpP has phosphodiesterase activity. 
Based on primary sequence homology, I hypothesized that the gene product 
of unknown function, previously annotated as Efc YybT, was a potential cyclic 
dinucleotide phosphodiesterase of the GdpP family (Efc GdpP) (Corrigan et al., 2011; 
Rao et al., 2010; Witte et al., 2013). Efc GdpP is a multi-domain protein containing 
two putative N-terminal transmembrane helices, a Per-Arnt-Sim (PAS) domain, a 
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GGDEF domain and a DHH domain with a DHHA1 subdomain (Figure 1.1) (Rao et al., 
2010). The PAS domain is a putative signal input module and is frequently involved 
in signal transduction in orthologous systems (discussed below) (Rao et al., 2011). 
The GGDEF domain often has diguanylate cyclase activity (discussed below) 
(Ryjenkov et al., 2005). Thus, based on homology (Figure 3.2), I postulated that the 
putative DHH/DHHA1 domain of Efc GdpP would have cyclic dinucleotide 
phosphodiesterase activity (Corrigan et al., 2011; Rao et al., 2010; Witte et al., 2013).  
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Figure 3.2 Alignment of DHH-DHHA1 domains. Figure shows the alignment of the 
DHH-DHHA1 domains of E. faecalis GdpP, Bacillus subtilis GdpP (referred as YybT in 
(Rao et al., 2010)), Staphylococcus aureus GdpP (Corrigan et al., 2011), Lactococcus 
lactis GdpP (Smith et al., 2012), Streptococcus pyogenes GdpP (Cho and Kang, 2013), 
Geobacillus thermodenitrificans GdpP (referred as YybT in (Rao et al., 2011)), and 
Mycobacterium tuberculosis phosphodiesterase Rv2837c (He et al., 2015). The 
44 
 
asterisks highlight the conserved residues for metal ion coordination with the 
alignment to M. tuberculosis Rv2837c (He et al., 2015). The triangles highlight the 
mutated residues Ile400, Asp419, and Asp499 in E. faecalis GdpP. Note that I440, the 
position mutated during adaptation to daptomycin is conserved (Miller et al., 2013). 
 
3.3.1. Efc GdpP has c-di-AMP specific phosphodiesterase in vitro. 
3.3.1.1. HPLC chromatography shows Efc GdpP hydrolyzes c-di-AMP to 5’pApA. 
To test whether Efc GdpP has phosphodiesterase, Efc GdpP and the 
DHH/DHHA1 domain (residues 309-658 referred to as GdpP309-658, Figure 1.1) were 
characterized in vitro. Purified wild type protein was incubated with c-di-AMP or c-
di-GMP, and the products were analyzed by reverse phase HPLC. As shown in Figure 
3.3A and Figure 3.3B, the incubation of GdpP with c-di-AMP resulted in the decrease 
of the cyclic dinucleotide peak and the formation of new product corresponding to 
linear dinucleotide 5’pApA without generating AMP or 3’pApA. This result indicates 
that Efc GdpP hydrolyzes c-di-AMP solely into 5’pApA and is consistent with the 
activity of B. subtilis GdpP measured previously (Rao et al., 2010). I also determined 
the phosphodiesterase activity of GdpP on c-di-GMP. Based on HPLC analysis, c-di-
GMP is not likely to be a physiological substrate of Efc GdpP, although it has a weak 
ability to hydrolyze c-di-GMP to 5’pGpG (Figure 3.3 C, D). 
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Figure 3.3 Efc GdpP has phosphodiesterase activity with specificity for c-di-
AMP. Reverse phase HPLC analysis of products from incubation of wild-type Efc GdpP 
and variants with cyclic dinucleotides at 28 °C for 2 h with 100 mM Tris pH 8.3, 20mM 
KCl, and 0.5mM MnCl2. Wild type Efc GdpP and c-di-AMP: (A) before and (B) after 
incubation. Wild-type Efc GdpP with c-di-GMP: (C) before and (D) after incubation. (E) 
Efc GdpPD419A/D499A after incubation with c-di-AMP. (F) Efc GdpPI440S after incubation 
with c-di-AMP.   
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3.3.1.2. Efc GdpP phosphodiesterase is more active in high pH range. 
The pH dependence of Efc GdpP activity was measured using reverse phase 
HPLC. Efc GdpP exhibited the highest enzymatic activity at pHs of 9.8 to 10.3 (Figure 
3.4). The optimal pH of Efc GdpP (9.8-10.1) is much higher than the optimal pH of its 
homolog B. subtilis GdpP, which is between 8.5 and 9.0 (Rao et al, 2010). 
 
Figure 3.4 pH dependence of Efc GdpP. 100mM Tris, 50mM CHES or 50mM CAPS 
were used to adjust pH. The reaction contained 20 mM KCl, 0.5 mM MnCl2. 10μM Efc 
GdpP and 100μM c-di-AMP. Assays were performed at 25˚C for 2 h before products 
were analyzed by reverse phase HPLC (see Materials and Methods). The area of 5’pApA 
peaks in the HPLC chromatography is plotted. 
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3.3.1.3. Mn+2 dependence of Efc GdpP phosphodiesterase activity. 
Once the specificity for c-di-AMP was established, I quantitated the 
phosphodiesterase activity using the coralyne fluorescence turn-on assay (Zhou et 
al., 2014). c-di-AMP, but not 5’pApA, can bind to the fluorescence dye coralyne and 
enhance its fluorescence emission (Zhou et al., 2014). Halide ions can quench the 
fluorescence of free coralyne to decrease the noise (Zhou et al., 2014). Since 
coralyne affected the binding of c-di-AMP to Efc GdpP, I could only perform end-
point assays to study phosphodiesterase activity. The original coralyne assay 
protocols published by Zhou et al. can only measure accurate c-di-AMP 
concentrations between 1 μM and 50 μM. By using filter plate (EconoSpin) to 
remove protein precipitates and trying different c-di-AMP/coralyne incubation 
conditions, I successfully optimized the protocols (please see Section 2.7 for details). 
The optimized coralyne assay can be used to accurately measure c-di-AMP 
concentrations between 1 μM and 2mM. 
Since divalent cations, such as Mn+2 and Mg+2, can activate B. subtilis GdpP 
phosphodiesterase activity in vitro (Rao et al., 2011), the Coralyne assay was first 
used to study the Mn+2 dependence of Efc GdpP phosphodiesterase activity. Figure 
3.5 shows the optimal concentration of Mn+2 is very broad with good activity from 
0.01mM to 1mM.  
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Figure 3.5 Mn+2 dependence of Efc GdpP phosphodiesterase activity. 5μM Efc 
GdpP was incubated with 80 μM c-di-AMP at 25˚C for 3 h before analyzed by the 
coralyne assay (Zhou et al., 2014). The reaction contained 50 mM CHES pH 9.2 and 
20mM KCl. 
 
3.3.1.4. Efc GdpP phosphodiesterase kinetics measured by coralyne 
fluorescence turn-on assay. 
I quantitated the phosphodiesterase activity of DHH/DHHA1 domain alone 
(Efc GdpP309-658) and the full-length protein using the coralyne activity assay 
fluorescence turn-on assay (Zhou et al., 2014). Activity for the full-length protein 
was weak (Figure 3.6A) and saturating conditions of c-di-AMP were not practical to 
establish, while the activity of Efc GdpP309-658 was ~13 times higher allowing me to 
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reach saturating conditions and establish kinetic parameters. The kinetic data for 
GdpP309-658 were clearly multiphasic and could be fit to two phases to produce two 
Kms extending over the conditions from 0-300 and 300-1750 μM c-di-AMP (Figure 
3.6B). The Michaelis-Menten reaction rate constants calculated separately for the 
two phases produce very similar values of kcat but a 3.3-fold change of Km (Km1= 
51.81 ± 8.42 μM, kcat1= 0.048 ± 0.003 s−1, Km2= 224.2 ± 30.26 μM, kcat2= 0.21 ± 0.01 
s−1) (Figure 3.6B).  
Since Efc GdpP309-658 was difficult to purify with a strong tendency to 
aggregate and adsorb non-specifically, protein aggregation might be one reason for 
the apparent multiphasic kinetics.  I screened 99 detergent reagents in different 
concentrations to help removing protein aggregation. I found that the detergent 
fluorinated octyl maltoside at 1 mM could reduce aggregation and produced protein 
that was 2 times more active (Km1= 443.6 ± 97.53 μM, kcat1= 0.42 ± 0.16 s−1, Km2= 
132.6 ± 20.05 μM, kcat2= 0.49 ± 0.01 s−1, please see Figure 3.6 D and E for data 
analysis) (Figure 3.6 D-F). Taken together, the poor behavior of the protein during 
purification and the importance of fluorinated octyl maltoside to increase activity 
suggests that the multiphasic kinetics I observed may reflect the tendency of the 
protein to adsorb/aggregate as a less active population and that increasing the 
substrate concentration to >300 mM mitigated that effect to increase activity.  
Alternatively, a conformational change within the DHH/DHHA1 domain could occur 
at higher c-di-AMP concentrations and be a physiological feature of GdpP. Thus, 
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when toxic levels of c-di-AMP are reached, GdpP phosphodiesterase activity may 
increase. 
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Figure 3.6 Steady-state kinetic analysis of E. faecalis GdpP DHH/DHHA1 
domain (Efc GdpP309-658) phosphodiesterase activity at 37oC. (A) Comparison of 
the phosphodiesterase activity of full-length Efc GdpP and Efc GdpP309-658. 10 μM Efc 
GdpP or 2.5 μM Efc GdpP309-658 were incubated with 1mM c-di-AMP at 37 oC. The 
reaction rates were normalized to 1μM protein. The reactions contained 50 mM CHES 
pH9.2, 20 mM KCl, and 0.5 mM MnCl2. (B) The enzymatic kinetics curve of Efc GdpP309-
658 without detergent. The reactions contained 2.5 μM Efc GdpP309-658, 50 mM CHES 
pH9.2, 20 mM KCl, and 0.5 mM MnCl2. (C-E) Steady-state kinetic analysis of Efc GdpP 
DHH/DHHA1 domain (Efc GdpP309-658) phosphodiesterase activity at 37 °C with 
detergent. The reaction contained 2.5 μM Efc GdpP309-658, 50 mM CHES pH 9.2, 20 mM 
KCl, 0.5mM MnCl2, and 1mM fluorinated octyl maltoside. To determine the reaction 
rate constants of the second stage (300-1750 μM c-di-AMP), the axis was shift from (0, 
0) to (300, 0.4348) (red) (D). V0=0.4348 was the mean of the reaction rates of 2.5 μM 
Efc GdpP309-658 with 300 μM c-di-AMP. In Figure (E) the kinetics curve was fit into one 
Michaelis-Menten model. (F) Kinetics comparison of Efc GdpP and Efc GdpP309-658 
without and with 1mM fluorinated octyl maltoside.  
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Table 3.2 Summary of Steady-state kinetics of c-di-AMP-specific phosphodiesterases in Gram-positive bacteria.  
 
aThe enzyme kinetics of E. faecalis S613 GdpP309-658 were measured in the presence of detergent (1mM fluorinated octyl 
maltoside). Please see Section 3.3.1.4 for details. 
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Table 3.2 shows the enzyme kinetics of Gram-positive bacterial c-di-AMP 
phosphodiesterases from previously published results. Efc GdpP309-658 shows similar 
kcat to other phosphodiesterases, but a much higher Km (Table 3.2). Since the 
intracellular c-di-AMP levels in B. subtilis were measured by a different method 
(~1.7 µM/1 L culture) (Oppenheimer-Shaanan et al., 2011b) and there is no report 
for c-di-AMP levels in M. smegmatis and M. tuberculosis., it is hard to explain the high 
Km of Efc GdpP309-658. Since the cellular c-di-AMP level in S. pneumoniae ST581 
(~25pM/OD620) is lower than that in Efc S613 (113±81 pM/OD600) (Bai et al., 
2013), the high Km of Efc GdpP309-658 may relate to the high c-di-AMP basal level in E. 
faecalis.  
Additionally, there are no enzyme kinetics studies for the c-di-AMP 
phosphodiesterase PgpH in enterococcus or other Gram-positive bacteria and 
therefore it is hard to predict which enzyme is the predominant phosphodiesterase 
in enterococci for c-di-AMP regulation in vivo. Previously published work has 
suggested that L. monocytogenes, PgpH is essential for regular cell growth, and thus 
GdpP plays an important role during bacterial virulence (Huynh et al., 2015). 
 
3.3.1.5. Aspartate 419 and 499 are essential to Efc GdpP phosphodiesterase 
activity. 
As the activity of Efc GdpP was low, I wished to eliminate any possibility that 
the modest phosphodiesterase activity observed by the HPLC and coralyne assays 
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were not the result of some contaminant. To do this I designed an inactive version of 
variant of the protein to link phosphodiesterase activity to Efc GdpP. Based on a 
comparison of the Efc GdpP sequence with that of others phosphodiesterases, Asp 
residues 419 and 499 are predicted to be ligands for the metal ion binding site 
required for phosphodiesterase activity (Figure 3.2 and Figure 3.7) (Rao et al., 
2010). To test whether Asp 419 and 499 are required for phosphodiesterase activity, 
I generated the double mutant Efc GdpPD419A/D499A.  As expected, no activity was 
detected after incubation of Efc GdpPD419A/D499A with c-di-AMP (Figure 3.3E). These 
results indicate that alignment of the primary sequences for Efc GdpP to other 
members of the DHH protein family phosphodiesterases has correctly identified 
residues essential to activity and support my conclusion that Efc GdpP is a bone fide 
cyclic dinucleotide phosphodiesterase.  
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Figure 3.7 Predicted structure of Efc GdpP. Predicted structure model of Efc GdpP 
DHH/DHHA1 domain indicating the presumptive phosphodiesterase active site and 
proximal position of I440S. Two Mn+2 ions are shown as spheres in magenta. Asp 
residues 419 and 499 are in blue, and Ile 440 is in orange. The structural model was 
built using the Phyre2 server. The Mn+2 positions are predicted by alignment with 
Mycobacterium tuberculosis phosphodiesterase Rv2837c (PDB 5CET) (He et al., 2015).  
 
3.3.2. Adaptive GdpP mutation I440S that correlates with daptomycin 
resistance in E. faecalis S613 strongly decreases GdpP phosphodiesterase 
activity in vitro. 
In Efc GdpP, the adaptive mutation I440S is located in the putative DHH 
domain (Figure 1.1), and is proximal to the predicted substrate binding site (Figure 
3.7) (He et al., 2015). To elucidate how the adaptive mutation may facilitate DAP 
resistance, I determined the phosphodiesterase activity of Efc GdpPI440S toward its 
potential physiological substrate c-di-AMP. As shown in (Figure 3.3F), incubation of 
c-di-AMP with GdpPI440S showed an 11-fold reduction in the ability to hydrolyze c-
di-AMP to 5’pApA.  Thus, the gdpPI440S was identified in the DAP adaptive isolates 
(Miller et al., 2013), and may lead to c-di-AMP accumulation in these strains, 
suggesting that high intracellular c-di-AMP levels are important for E. faecalis 
physiology during DAP induced membrane stress. 
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3.3.3. Efc GdpP regulates E. faecalis intracellular c-di-AMP level. 
To further test whether Efc GdpP has phosphodiesterase activity in vivo, the 
gene coding wild-type Efc GdpP was subcloned into the nisin-inducible vector 
pMSP3535 (Bryan et al., 2000)  and transformed into Efc OG1RF. As shown in Figure 
3.8 and Table 3.1, overexpression of Efc GdpP decreased cellular c-di-AMP levels by 
about 27% when compared to the empty plasmid. The decreased c-di-AMP levels in 
cells expressing Efc GdpP from the plasmid pMSP3535 were statistically significant 
compared with the control strain (p=0.008).  
Since Efc GdpPI440S showed decreased phosphodiesterase in vitro, I expected 
that expression of the mutant Efc GdpPI440S from the plasmid pMSP335 would lead 
to restored levels of c-di-AMP. While there was a very modest decrease in c-di-AMP 
levels, it was not statistically significant (p=0.078). There could be a number of 
reasons for the inability of Efc GdpPI440S to fully restore c-di-AMP levels compared 
with negative control (OG1RF::pMSP3535). First, the mutation I440S decreases the 
phosphodiesterase activity by around 11-fold, but does not completely abolish it. 
Second, since Efc GdpPI440S is being expressed along with the genomic copies of the 
wild type GdpP in addition to the c-di-AMP synthesis and regulatory genes, the net 
effect of the Efc GdpPI440S might be compensated for by the homeostatic machinery 
of the cell. I observed a slight c-di-AMP level increase in Efc OG1RF:: pMSP3535 
compared with Efc OG1RF (158±3 pM/OD600 versus 112±47 pM/OD600, p=0.225, see 
Table 3.1, Figure 3.1, and Figure 3.8 for details), which may be caused by addition of 
nisin, since higher c-di-AMP levels were also detected when Efc OG1RF::pMSP3535 
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when cultured with nisin versus its absence (data not shown).  Together, my data 
highly suggest that Efc GdpP has phosphodiesterase activity in vivo, and can regulate 
intracellular c-di-AMP levels.  
 
 
Figure 3.8 Expression of the c-di-AMP phosphodiesterase Efc GdpP in trans 
leads to reduced c-di-AMP levels in vivo. Intracellular concentrations of c-di-AMP 
in Efc OG1RF during expression of Efc GdpP or Efc GdpPI440S. Expression of Efc GdpP 
leads to a statistically decreases in c-di-AMP levels (~27%). Expression of Efc GdpPI440S 
does not lead to significant changes in c-di-AMP.  Each strain has three biological 
independent measurements. 
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3.3.4. E. faecalis GdpPI440S is more sensitive to inhibition by ppGpp in vitro. 
Several studies on GdpP family proteins, such as B. subtilis GdpP and S. 
aureus GdpP, have reported that ppGpp can inhibit GdpP phosphodiesterase activity 
(Corrigan et al., 2015; Rao et al., 2010). ppGpp is a stringent response signaling 
molecule, and accumulates in some bacteria during nutrient starvation (Kalia et al., 
2013). In B. subtilis, ppGpp binds to B. subtilis GdpP, and inhibits phosphodiesterase 
activity (referred to as YybT in (Rao et al., 2010)).  
To determine whether ppGpp is a direct inhibitor of Efc GdpP, 1mM ppGpp 
was incubated with 10 μM Efc GdpP and 100 μM c-di-AMP. Figure 3.9A shows that 
ppGpp inhibits Efc GdpP phosphodiesterase activity very modestly, but does not 
completely abolish it, even though the molar ratio of c-di-AMP to ppGpp was 10:1. 
My data suggests that ppGpp is a very weak inhibitor of Efc GdpP phosphodiesterase 
activity in vitro.  
When 1mM ppGpp was added to the reaction system of 10μM Efc GdpPI440S 
and 100μM c-di-AMP, no c-di-AMP was hydrolyzed to 5’pApA after incubation for 2 
h (Figure 3.9B) and indicates that the residual phosphodiesterase activity of Efc 
GdpPI440S can be inhibited by ppGpp in vitro.  This data suggests that Efc GdpPI440S 
could be more sensitive to ppGpp inhibition than wild type Efc GdpP in vivo.  
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Figure 3.9 ppGpp is able to modestly inhibit Efc GdpP phosphodiesterase 
activity. (A) Reverse phase HPLC analysis of products from incubation of wild type Efc 
GdpP and c-di-AMP with (red) and without (black) 1mM ppGpp after incubation for 2 
h at 28oC. (B) Efc GdpPI440S with c-di-AMP and ppGpp after 2hr incubation at 28oC 
showing no significant 5’pApA production. 
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3.4. Efc GdpP has ATPase activity, but not diadenylate cyclase 
activity in vitro. 
3.4.1. Efc GdpP has ATPase activity in vitro. 
Efc GdpP has a putative GGDEF domain which is unusual as the previously 
described GdpP family proteins typically lack the conserved GGDEF motif (Cho and 
Kang, 2013; Corrigan et al., 2011; Rao et al., 2010, 2011). Proteins containing GGDEF 
domains in Gram-negative bacteria often have diguanylate cyclase activity, which 
can synthesize c-di-GMP from 2 GTPs  (Ryjenkov et al., 2005). But the GGDEF 
domain in B. subtilis GdpP has only a very weak ATPase activity (referred to as YybT 
in (Rao et al., 2010)).  
Primary sequence alignment indicated that Efc GdpP (similar to B. subtilis 
GdpP) contains a modified GGDEF domain with a highly divergent amino acid 
sequence (Figure 3.10). The GGDEF domain in B. subtilis GdpP, can bind ATP and 
slowly convert it to ADP (Rao et al., 2010). To test whether Efc GdpP exhibited 
ATPase activity, I incubated 100 μM ATP with 10 μM Efc GdpP, and analyzed the 
products by reverse phase HPLC. The chromatographic analysis revealed that Efc 
GdpP could hydrolyze ATP leading to the formation of ADP after incubation (Figure 
3.11A, B).  
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Figure 3.10 Proposed Alignment of the GGDEF domains. Proposed alignment of 
the GGDEF domains of E. faecalis GdpP, Bacillus subtilis GdpP (referred as YybT in 
(Rao et al., 2010)), Staphylococcus aureus GdpP (Corrigan et al., 2011), Streptococcus 
pyogenes GdpP (Cho and Kang, 2013), Geobacillus thermodenitrificans GdpP (referred 
as YybT in (Rao et al., 2011)), and the GGDEF domain in Caulobacter crescentus PleD 
with diguanylate cyclase activity (Paul et al., 2004). The conserved GGD(E)EF motif is 
highlighted. 
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Figure 3.11 . Efc GdpP and GdpPI440S have comparable ATPase activity. (A-C): 
Reverse phase HPLC analysis of: (A) ATP and wild-type Efc GdpP before incubation, (B) 
ATP and wild-type Efc GdpP after 2 h incubation at 25°C, (C) ATP and Efc GdpPI440S 
after 2 h incubation at 2562°C. (D) ATPase activity measurement of 5 μM Efc GdpP 
28°C. (E) ATPase activity measurement of 5μM Efc GdpPI440S 28°C. Reaction buffer 
contains 50mM Tris pH 7.5, and 1mM MgCl2. (F) ATP inhibition of the Efc GdpP ATPase 
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activity. Reverse phase HPLC results of 10µM Efc GdpP incubated with 2 mM and 6 mM 
ATP at 28˚C. The area of the peaks corresponding to ADP are plotted. The reaction 
buffer contained 40 mM Tris pH7.5 and 10 mM MgCl2. 
 
3.4.2. Efc GdpP ATPase kinetics curve shows substrate inhibition. 
To quantitate Efc GdpP ATPase kinetics, I used the EnzChek® Phosphate 
Assay Kit (Life Technologies). Efc GdpP can hydrolyze ATP to generate inorganic 
phosphate (Pi), which can interact with 2-amino-6-mercapto-7-methylpurine 
ribonucleoside (MESG, Absmax=340nm) to produce 2-amino-6-mercapto-7-
methylpurine (Absmax=360nm) (Upson et al., 1996). Thus, the ATPase reaction 
kinetics can be readily quantified. (Please see Chapter 2 for details.) 
ATPase activity of Efc GdpP had a kcat of 0.80 ± 0.03 min-1 and Km of 239.2 ± 
41.8 μM (Figure 3.11D), while the B. subtilis GdpP homolog had similar values of kcat 
but a markedly lower Km (kcat= 0.59 ± 0.03 min−1, Km= 0.90 ± 0.12 mM) (Rao et al., 
2010).   
To assess whether the mutation of Ile-440 to Ser in the DHH domain could 
affect ATPase activity in the GGDEF domain, I measured the ATPase activity of Efc 
GdpPI440S. ATPase activity for Efc GdpPI440S was comparable to wild type GdpP (Fig. 
6C) with a kcat of 1.12 ± 0.02 min-1 and Km of 287.5 ± 20.2 μM (Figure 3.11E). Thus, it 
appears that the mutation I440S in the DHH domain does not affect the GGDEF 
domain ATPase activity (p=0.880).  
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The weak ATPase activity of GdpP required me to use up to 2 mM ATP to 
provide sufficient data for the analysis. When performing the ATPase studies, I 
observed unexpected substrate inhibition on the ATPase activity (Figure 3.11 D and 
E). Interestingly, inhibition starts at about 2.5 mM ATP which is in the range of its 
intracellular concentration (about 1-10 mM) (Yaginuma et al., 2014). To confirm 
that the inhibition was not caused by the reagents used in the colorimetric ATPase 
assay, I incubated 10 µM Efc GdpP with 2 mM and 6 mM ATP at 28°C respectively, 
and analyzed the products directly by reverse phase HPLC (Figure 3.11F). This data 
suggested that in vitro substrate inhibition could be biologically relevant and led me 
to suspect that the local cellular ATP concentration around the cell membrane could 
alter Efc GdpP ATPase activity.  
3.4.3. Efc GdpP does not show diadenylate cyclase activity in vitro. 
A study of S. aureus GdpP showed that two mutations in its GGDEF domain 
could increase antibiotic resistance against vancomycin and oxacillin, and that 
complementation with an S. aureus GdpP N-terminal truncation with an inactive 
DHH domain could restore antibiotic susceptibility (Griffiths and O’Neill, 2012). 
Together these observations suggest that the Efc GdpP GGDEF domain has 
additional activities in vivo beyond weak ATP hydrolysis. It seems likely that ATP is 
hydrolyzed as part of another activity of the domain and thus I sought to identify 
alternate activities or conditions that might stimulate any potential GdpP cyclase 
activity. 
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Recently, the GGDEF domains from deltaproteobacteria were reported to 
have a hybrid dinucleotide cyclase activity, and can synthesize c-di-AMP, c-di-GMP, 
and cyclic AMP-GMP (3’,3’-cGAMP), which suggests the GGDEF domains have similar 
dinucleotide cyclase  (Hallberg et al., 2016).  
To identify whether Efc GdpP GGDEF has di-nucleotide cyclase activity, Efc 
GdpP purified from E. coli was incubated with 0.1mM, 2mM, and 6mM ATP or GTP. 
Potential cofactors, such as heme and NADH, and reducing agents were tested. After 
optimizing reaction conditions, incubation of Efc GdpP with ATP or GTP did not 
produce either c-di-AMP or c-di-GMP (data not shown). One potential reason was 
that c-di-GMP in E. coli binds to the I-site of GGDEF domain, inhibiting the 
dinucleotide cyclase activity. The other possibility is that the protein was expressed 
in E. coli, lacking the cofactor in enterococci for dinucleotide cyclase activity. 
Efc GdpP residue tyrosine 212 was in the putative GGDEF domain I-site. To 
preventing the potential binding of di-nucleotides to I-site, I generated the I-site 
mutant Efc GdpPY212A. To avoid degrading of di-nucleotide by the N-terminal 
DHH/DHHA1 domain, I also tested Efc GdpPD419A/D499A and Efc GdpPY212A/D419A/D499A.  
To allow wild-type Efc GdpP and its three variants to bind the potential co-
factors in enterococci, proteins were incubated with Efc S613 cell extracts, and 
purified by Ni-NTA affinity chromatography. Proteins were then incubated with 
1mM – 16mM ATP. The generation of c-di-AMP was tested by c-di-AMP competitive 
ELISA, which is an accurate method to detect low-concertation (≥2nM) c-di-AMP 
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(Underwood et al., 2014). However, after optimizing reaction conditions, no c-di-
AMP was observed. It appears that the GGDEF domain is not a c-di-AMP or c-di-GMP 
synthase in vitro or that I was unable to identify appropriate conditions to stimulate 
cyclase activity.    
3.5. The PAS domain in E. faecalis GdpP does not appear to bind 
heme in vitro. 
Small Per-ARNT-Sim (PAS) domains usually function as input domains in 
proteins to respond to a variety of stimuli, including light and small ligands via 
different co-factors associated with the PAS fold (Taylor and Zhulin, 1999). 
Previously, it had been reported that PAS domains of Efc GdpP homologs in B. 
subtilis and G. thermodenitrificans are capable of binding heme, as a co-factor 
resulting in suppressing the phosphodiesterase activity in vitro (Rao et al., 2011).  
In this study, heme reconstitution assays were performed to determine 
whether the PAS domain in Efc GdpP can function as sensor domain for recognizing 
an environmental signal through a heme cofactor. 1mM heme (in 10mM NaOH) was 
titrated into His-tagged or GST-tagged Efc GdpP solutions at 37˚C to a final 1:1 molar 
ratio. Their UV absorbance was scanned every 1min. 
As shown in Figure 3.12A, upon addition of heme, the UV spectrum of His-Efc 
GdpP showed decreases in the absorbance maxima corresponding to free heme 
(373nm, 630nm), whereas the absorbance maxima of hexacoordinate heme 
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(415nm, 542nm, 575nm) increased. My data suggests that heme binds to His-Efc 
GdpP but I was concerned that the His-tag may provide good ligands for heme in a 
non-physiological context (Owens et al., 2012). Although there was a TEV protease 
cleavage site, unfortunately, the His-tag could not be removed by TEV protease. I 
replaced the His-Tag with a GST-tag to test the heme-binding ability of a Efc GST-
GdpP to rule out the potential interference of His-tag. I incubated GST-Efc GdpP with 
heme for 6 h at 37˚C, there was no spectroscopic signal for a hexacoordinated heme 
(Figure 3.12B), suggesting GST-Efc GdpP could not bind heme. My data suggests that 
the His-tag was indeed responsible for my earlier finding and that Efc GdpP did not 
bind heme under these conditions. I have not identified a cofactor for the PAS 
domain in Efc GdpP however this remains under investigation. 
 
Figure 3.12 Heme reconstitution assays show Efc GdpP doesn’t bind heme in 
vitro. (A) UV absorbance of Efc His-GdpP with heme titration at 37˚C. The reaction 
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condition contains 25mM CHES pH8.6, 200mM NaCl. (B) UV absorbance of Efc GST-
GdpP with heme titration at 37˚C. The reaction contained 50mM Tris pH8.0, 200mM 
NaCl. 
 
3.6. Discussion 
Cyclic dinucleotide signaling in bacteria is widespread and is linked to a 
variety of regulatory responses including DNA integrity reporting (Oppenheimer-
Shaanan et al., 2011a), cell wall biosynthesis (Corrigan et al., 2011), potassium 
homeostasis (Corrigan et al., 2013) and biofilm formation (Corrigan et al., 2011). 
Experimental evolution of a polymorphic population of Efc S613 to daptomycin 
resistance using a continuous evolution bioreactor identified a point mutation 
(yybTI440S) in a gene of unknown function initially named yybT (Miller et al., 2013). 
Based on primary sequence identity, I postulated that YybT might in fact be a cyclic 
dinucleotide phosphodiesterase, and based on my studies I have established 
phosphodiesterase activity consistent with classification as a member of the GdpP 
family. Therefore, I have changed the name to GdpP. As c-di-AMP signaling in 
enterococci had not been established, I first tested if c-di-AMP was present at levels 
consistent with a role in in vivo signaling (from 44 pM/OD600 to 1133 pM/OD600, 
Figure 3.1 and Table 3.1). Having established that c-di-AMP was present in vivo, I 
went on to confirm the role of the novel GdpP in c-di-AMP homeostasis.  
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As shown in Figure 1.1, GdpP is comprised of three distinct domains. I 
purified and characterized full-length Efc GdpP as well as the DHH/DHHA1 domain 
(Efc GdpP309-658). My results showed that Efc GdpP is indeed a cyclic-di-AMP 
phosphodiesterase with a strong preference for c-di-AMP over c-di-GMP. Efc 
GdpPI440S shows little phosphodiesterase activity and, as expected, strains encoding 
Efc GdpPI440S have increased cyclic-di-AMP levels in vivo. My results showed that 
expression of Efc GdpP from an inducible vector pMSP3535 in wild-type Efc OG1RF 
decreased cellular c-di-AMP level by 27% (Figure 3.8 and Table 3.1). Although I 
could demonstrate weak ATPase activity for the GGDEF domain and c-di-AMP 
phosphodiesterase activity for the DHH/DHHA1 domain, I was unable to identify the 
in vivo function of either domain. The PAS domain could be a critical regulator of the 
activities of the GGDEF and DHH/DHHA1 domains in vivo. For example, the c-di-
AMP phosphodiesterase activity for the DHH/DHHA1 domain alone (GdpP309-658) is 
~13 times higher than the full-length protein suggesting that under specific 
conditions or stimuli in vivo, the kinetic rates of the activities within the GdpP 
domains may be quite variable and well regulated. Undoubtedly, each of the GdpP 
domains has relevant activities or roles in vivo. A study showed S. aureus GdpP 
GGDEF mutations could increase S. aureus vancomycin and oxacillin resistance 
(Griffiths and O’Neill, 2012). Together, these observations suggest that the Efc GdpP 
GGDEF domain has additional activities in vivo beyond weak ATP hydrolysis. 
However, I couldn’t detect Efc GdpP di-nucleotide cyclase activity in vitro. The 
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functional role of the PAS and GGDEF domains is the subject of ongoing 
investigation.  
Based on sequence homology, E. faecalis has only one gene coding a potential 
c-di-AMP synthase (cdaA, also referred as ybbP) (Mehne et al., 2013). My finding of a 
robust c-di-AMP pool in E. faecalis suggests that Efc CdaA is active in vivo. E faecalis 
has two potential genes encoding c-di-AMP phosphodiesterases, gdpP and pgpH 
(Huynh et al., 2015). The Listeria monocytogenes PgpH is a membrane protein, and 
can hydrolyze c-di-AMP to 5’pApA via a His-Asp (HD) domain (Huynh et al., 2015). A 
study of L. monocytogenes c-di-AMP phosphodiesterases showed that DHH/DHHA1 
family phosphodiesterases are more important than HD family phosphodiesterases 
for bacterial virulence and intracellular growth (Huynh et al., 2015), which may be 
the reason that I did not observe mutations in PgpH in the clinical or experimental 
evolution data for enterococci.  
In summary, I show that c-di-AMP is present in enterococci, and that a novel 
GdpP phosphodiesterase, previously associated with daptomycin resistance, is 
important to modulate c-di-AMP in response to cell membrane damage caused by 
the antibiotic. 
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Chapter 4 
The LiaFSR-XYZ regulon interacts with the 
c-di-AMP signaling network. 
4.1. Introduction 
During adaptation to DAP, Miller et al. observed that the first step towards 
resistance was a family of mutations that, in the LiaFSR and LiaX membrane stress 
response pathway (Miller et al., 2013; Tran et al., 2013). In two of the evolutionary 
trajectories leading to DAP resistance, an Ile to Ser substitution at position 440 was 
observed in GdpP (Miller et al., 2013). Interestingly, GdpPI440S was always found in 
association with a LiaR mutant (LiaRD191N), suggesting a potential epistatic link 
between changes in LiaFSR signaling and GdpP (Miller et al., 2013). Since LiaR is the 
response regulator of the LiaFSR membrane-stress response system (Wolf et al., 
2010), I investigated the possibility that the LiaFSR pathway effected levels of c-di-
AMP. 
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In this chapter, I show that mutations in the LiaFSR and LiaXYZ pathways can 
affect intracellular c-di-AMP levels, suggesting Lia pathways are linked to c-di-AMP 
regulated metabolism. I also show that intracellular c-di-AMP levels change with 
DAP treatment, which suggests c-di-AMP participates in the cell membrane stress 
response. In the course of these studies I also show a new putative phosphodiesterase 
XpaC that is under LiaFSR regulation. 
4.2. Mutations in the LiaFSR signaling pathway can affect 
intracellular c-di-AMP levels. 
4.2.1. LiaR deletion leads to increased c-di-AMP level. 
To test whether LiaFSR leads to changes in intracellular c-di-AMP regulation, 
I initially used a strain in which our collaborator had generated a non-polar deletion 
of liaR in Efc. Cell extracts from the mutant Efc OG1RF_ΔliaR (Table 3.1) were tested 
for c-di-AMP levels. Of note, the liaR deletion removes the response regulator of the 
LiaFSR pathway, effectively “shutting off” the LiaFSR system. Deletion of liaR (Efc 
OG1RF_ΔliaR) upregulated the levels of c-di-AMP to 351±94 pM/OD600 (Figure 4.1A 
and Table 3.1), a more than 3-fold increase compared to wild type Efc OG1RF 
(p=0.030). When liaR expression was restored in cis in Efc OG1RF_ΔliaR (Efc 
OG1RF_ΔliaR::liaR, Table 3.1), cellular c-di-AMP levels returned to the levels 
observed for wild type Efc OG1RF (140±29 pM/OD600, p=0.436, Figure 4.1A and 
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Table 3.1). These results suggest that decreases in LiaFSR signaling leads increases 
in intracellular c-di-AMP levels. 
To demonstrate that changes in LiaFSR signaling also lead to c-di-AMP 
changes in other enterococcal strains, I measured the c-di-AMP levels in non-polar 
deletion mutants of liaR in E. faecium strains HOU503F and R497F (Efm 
HOU503F_ΔliaR and Efm R497F_ΔliaR, Table 3.1) which are tolerant and resistant to 
DAP respectively (Panesso et al., 2015). As observed with E. faecalis, deletion of liaR 
in Efm HOU503F_ΔliaR and Efm R497F_ΔliaR showed modest increases in c-di-AMP 
levels when compared to Efm HOU503F and Efm R497F (622±104 pM/OD600 vs. 
542±133 pM/OD600, and 736±186 pM/OD600 vs. 549±150 pM/OD600, Figure 4.1B 
and Table 3.1) but the increases were not statistically significant (p = 0.250 and 
0.461). It is interesting that the inactivation of the LiaFSR pathway in E. faecium 
does not increase c-di-AMP concentrations to the same extent as observed in E. 
faecalis. The basal level of c-di-AMP in E. faecium HOU503F and R497F was much 
greater than E. faecalis OG1RF or S613 and thus there are substantial differences in 
the basal c-di-AMP pools of these related organisms. The reason for the higher 
baseline levels in E. faecium is unclear but may account for my inability to measure 
statistically relevant differences in c-d-AMP levels as the differences of Efm 
HOU503F and Efm R497F to their respective LiaR knockouts was much closer in E. 
faecium (622±104 pM/OD600 vs. 542±133 pM/OD600, and 736±186 pM/OD600 vs. 
549±150 pM/OD600, Figure 4.1B). Since very high levels of c-di-AMP have been 
associated with decreased fitness (Mehne et al., 2013) there may be an upper end to 
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c-di-AMP levels beyond which there is substantial toxicity and E. faecium is already 
near that range of c-di-AMP concentrations. Cis-complementation with liaR 
decreased the intracellular c-di-AMP levels to 505±54 pM/OD600 and 525±134 
pM/OD600 for Efm HOU503F_ΔliaR::liaR and Efm R497F_ΔliaR::liaR, respectively, 
similar to the c-di-AMP levels in wild-type strains (Figure 4.1B and Table 3.1).  
 
Figure 4.1 Enterococci strains with mutations in the LiaFSR signaling pathway 
have increased c-di-AMP levels. Intracellular c-di-AMP concentrations were 
measured by an enzyme-linked immunosorbent assay (ELISA) (Underwood et al., 
2014). c-di-AMP was detected in both of E. faecalis (A) and E. faecium (B). (A) E. 
faecalis strains: The intracellular c-di-AMP level in Efc OG1RF_ΔliaR that knocks out 
LiaFSR signaling increases to 351±94 pM/OD600 (Underwood et al., 2014), 
complementation of liaR in cis restores c-di-AMP levels. (B) E. faecium strains: the non-
polar deletion mutant of liaR causes a small but not statistically-significant increase in 
Efm HOU503F_ΔliaR and Efm R497F_ΔliaR. Each c-di-AMP measurement was made 
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from at least three independent biological measurements. (See Table 3.1 for strain 
descriptions.) 
 
4.2.2. LiaFSR does not directly regulate the expression of c-di-AMP synthase 
CdaA and phosphodiesterase GdpP and PgpH. 
Since deletion of LiaR in Efc OG1EF lead to increased c-di-AMP levels, I 
performed quantitative PCR (qPCR) on the putative target genes in Efc OG1RF and 
Efc OG1RF_ ΔliaR to observe whether LiaFSR directly regulates c-di-AMP signals. 
As expected, deletion of liaR effectively turned off LiaFSR pathway, and down 
regulated the transcription of liaFSR and liaXYZ, which are under LiaR regulation 
(Figure 4.2A) (Miller et al., 2013). However, qPCR of the potential target genes gdpP, 
pgpH, cdaA and cdaR did not show significant changes in transcription (Figure 4.2B). 
CdaA is the only known c-di-AMP synthase in Efc OG1RF, and CdaR is the regulator 
of CdaA (Rismondo et al., 2016; Rosenberg et al., 2015). GdpP and PgpH are c-di-
AMP phosphodiesterases (Huynh et al., 2015). My data suggests that LiaFSR 
pathway regulate cellular c-di-AMP levels indirectly. For example, changes in LiaFSR 
signaling are known to alter pools of lipids and many other aspects of cellular 
physiology that are likely to be integrated within other regulatory networks that 
may, in turn, alter c-di-AMP levels (Reyes et al., 2015).  
At present the only molecule known to regulate c-di-AMP phosphodiesterase 
activity is the inhibitor ppGpp (Section 3.3.4). Efc has two putative ppGpp synthases, 
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RelA and RelQ (Abranches et al., 2009). If LiaFSR regulates c-di-AMP degradation 
through ppGpp, the expression of ppGpp synthases should decrease in Efc OG1RF_ 
ΔliaR. However, I did not detect significant changes of relA and relQ expression with 
deletion of LiaR in Efc OG1RF (Figure 4.2B). 
All of these observations suggest there are still as yet unidentified regulatory 
mechanisms interacting with the LiaFSR regulon to alter c-di-AMP levels. It is 
certainly possible that the as yet unknown activities of the Efc GdpP PAS and 
regulation of the DHH/DHHA1 domains may be the critical ‘missing piece’ of the 
puzzle that links LiaFSR to other regulatory networks. During my studies, I 
discovered a novel putative c-di-AMP phosphodiesterase XpaC which is under LiaR 
regulation and this will be discussed further in Section 4.4. 
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Figure 4.2 . Quantitative PCR of putative LiaFSR regulons and c-di-AMP related 
genes in E. faecalis OG1RF_ΔliaR. Transcription was analyzed in Efc OG1RF and Efc 
OG1RF_ΔliaR. The non-polar deletion mutant of liaR removes the response regulator of 
the LiaFSR pathway, effectively “shutting off” the LiaFSR system. The transcription of 
liaFSR and liaXYZ operons are directly under LiaR regulation (Miller et al., 2013), and 
were down-regulated by deletion of liaR. Gene transcript levels of gdpP (coding c-di-
AMP phosphodiesterase), pgpH (coding a putative c-di-AMP phosphodiesterase), cdaA 
(coding c-di-AMP synthase A, CdaA), cdaR (coding CdaR, a regulator of CdaA), relA and 
relQ (coding ppGpp synthase RelA and RelQ) did not change significantly with LiaR 
deletion (Abranches et al., 2009; Huynh et al., 2015; Rismondo et al., 2016, 2016).  
 
4.3. The LiaXYZ regulon interacts with the c-di-AMP network. 
In addition to the adaptive mutations in LiaR and LiaF in response to DAP, a 
frame-shift mutation in a previously uncharacterized operon liaXYZ was also 
identified (LiaXV289fs: previously referred as YvlBV289fs) (Miller et al., 2013). The roles 
LiaX, LiaY and LiaZ play in bacteria is still unclear but is under active investigation in 
our lab. LiaY (also referred as PspC) and LiaZ (also referred as YvlD) are membrane 
proteins (Davlieva et al., 2015a). LiaX (also referred as yvlB) is a potential signal 
sensor and interacts with LiaYZ (Davlieva et al., unpublished work). Since LiaX 
mutant was identified in DAP-resistant E. faecalis, and LiaX in under LiaR regulation, 
we hypothesized that LiaXYZ is embedded within the larger c-di-AMP network. 
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4.3.1. LiaX defects do not alter c-di-AMP signaling. 
To test whether LiaX regulates cellular c-di-AMP levels, I first measured the 
c-di-AMP concentrations in Efc S613, and the experimental DAP-resistant strain Efc 
TDR7 with mutation liaXV289fs and cardiolipin synthase (clsR217Q) (Table 3.1) (Miller 
et al., 2013). As shown in Figure 4.3 A and B, the c-di-AMP concentration in Efc 
TDR7 was 2.4-fold higher than Efc S613 (268±97 pM/OD600 versus 113±81 
pM/OD600) (Table 3.1), and did not change with DAP treatment. To rule out the 
possibility that clsR217Q in Efc TDR7 interferes c-di-AMP signaling, I tested c-di-AMP 
levels in wild-type Efc OG1RF, Efc OG1RF_liaX1-289, and Efc OG1RF_ΔliaX (Table 3.1). 
Neither liaX1-289 or ΔliaX affected intracellular c-di-AMP concentrations in Efc 
OG1RF (Figure 4.3 C and D), suggesting that LiaX defects are not enough to affect c-
di-AMP signaling. On the other hand, Efm S447 CLSR218Q, clsR217Q alter cardiolipin 
synthase activity which, in turn,  alters cell membrane properties (Davlieva et al., 
2013) that could certainly be linked indirectly to c-di-AMP levels. My data suggests 
c-di-AMP can report cell membrane changes, and participates in antibiotic-induced 
cell membrane stress response. 
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Figure 4.3 Intracellular c-di-AMP concentrations in Efc liaXYZ deficient strains.  
Intracellular c-di-AMP concentrations were measured in Efc liaXYZ deficient strains by 
an enzyme-linked immunosorbent assay (ELISA) (Underwood et al., 2014). (A) The c-
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di-AMP levels in Efc S613 did not change with DAP treatment. (B) The c-di-AMP levels 
in Efc TDR7 were 2.4-fold higher than wild type, and did not change under DAP 
treatment. (C-D) liaX defects did not affect c-di-AMP concentration in Efc OG1RG, 
suggesting LiaX itself could not affect c-di-AMP signaling. (E) c-di-AMP concentrations 
decreased with LiaYZ defects. And c-di-AMP levels increased with higher DAP 
concentrations, suggesting LiaYZ was involved in c-di-AMP regulation.  Each c-di-AMP 
measurement was made from at least three independent biological measurements. 
(See Table 3.1 for strain descriptions.) 
 
4.3.2. LiaY and LiaZ are involved in c-di-AMP signaling.  
As mentioned previously, LiaY and LiaZ are predicted to be membrane 
proteins (Davlieva et al., 2015a). The functions of LiaY and Z are still unclear, but as 
liaY and liaZ are in the same operon as liaX and under the regulation of LiaFSR, we 
reasoned that LiaYZ may be linked to the regulation of intracellular c-di-AMP levels.  
To test this possibility, cell extracts from strains where liaYZ were knocked 
out (Efc OG1RF_ΔliaY, Efc OG1RF_ΔliaZ, and Efc OG1RF_ΔliaYZ) were examined 
(Table 3.1). In Efc OG1RF_ΔliaY, c-di-AMP levels decreased 77% to 26±33 pM/OD600 
(Figure 4.3E and Table 3.1). In Efc OG1RF_ΔliaZ, c-di-AMP levels decreased 88% to 
14±7 pM/OD600 (Figure 4.3E and Table 3.1). Deletion of LiaYZ also led to a 43% c-di-
AMP decrease to 64±12 pM/OD600 (Figure 4.3E and Table 3.1). 
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liaYZ defects also made Efc OG1RF behave differently during DAP exposure. 
With 1 µg/ml DAP, the c-di-AMP levels in Efc OG1RF showed only a moderate 
decrease (Figure 4.3E). But c-di-AMP in Efc OG1RF_ΔliaYZ increased significantly 
with increased DAP treatment (Figure 4.3E). All of these data suggests LiaY and LiaZ 
are part of the larger c-di-AMP network. 
4.4. XpaC is a putative c-di-AMP phosphodiesterase under LiaR 
regulation. 
As discussed in Section 4.2, ‘shutting off’ the LiaFSR pathway leads to 
increased c-di-AMP levels in Efc, but the genes related to c-di-AMP synthesis and 
degradation (cdaA, gdpP and pgpH )are not under direct LiaR regulation (Figure 4.2). 
Taken together my data suggests that enterococci have as yet undiscovered c-di-
AMP synthase/phosphodiesterases. I found one Efc S613 derived strain 
S613_D18A10 generated from the DAP adaptation assays showing up to ~14-fold 
higher c-di-AMP levels than wild-type Efc S613 (1493±61 pM/OD600 versus 113±81 
pM/OD600, Figure 4.4A), suggesting an important c-di-AMP regulator may have been 
mutated in its genome. I so analyzed the Efc S613 derived strains to find putative 
genes. 
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Figure 4.4 c-di-AMP levels in Efc S613 derived DAP-resistant strains. c-di-AMP 
concentrations in Efc S613_D17C9 and Efc_D18A10 measured by an enzyme-linked 
immunosorbent assay (ELISA) (Underwood et al., 2014). Each c-di-AMP measurement 
was made from at least three independent biological measurements. Please see Table 
3.1 and Table 4.1 for strain descriptions.  
 
4.4.1. Whole genome sequencing results of E. faecalis S613 derivative strains. 
Two DAP-resistant S613 derivative strains Efc S613_D17C9 and Efc 
S613_D18A10 were analyzed by whole genome sequencing (Table 4.1).  
Efc S613_D17C9 has liaFΔI177, produces a constitutively “on” state of the 
LiaFSR pathway (Miller et al., 2013). Two additional mutations not observed in that 
earlier study by Miller et al., (2013) were identified in this strain, including a silent 
mutant prgUG105G (with unknown function), and a 34bp intergenic deletion between 
cspA (coding a putative cold-shock DNA-binding domain protein) and EFE19808.1 
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(coding a YdcF-like hypothetical cytidylyltransferase family protein). These new 
mutations were likely missed in our earlier studies because the reference genomes 
available at that time had significant gaps between contigs and thus the genomes 
were not closed. 
Efc S613_D18A10 has liaFΔI177 and 5 additional mutations (Table 4.1). 
Besides the same 34bp intergenic deletion (cspA/EFE19808.1) as in S613_D17C9, 
and a silent mutant prgUN103N, Efc S613_D18A10 also has xpaCK163fs (coding 
5-bromo-4-chloroindolyl phosphate hydrolysis protein), dacAE554K (coding 
D-alanyl-D-alanine carboxypeptidase), and an intergenic mutation GT between 
EFE19514.1 (coding a hypothetical protein) and EFE19513.1 (coding a putative ABC 
transporter or a putative permease).      
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Table 4.1 Genotypes of E. faecalis S613 derivative strains. 
 
 Strains Genotype Description 
S613_D17C9 
liaFΔI177 LiaFΔI177 is supposed to keep LiaFSR pathway in ‘on’ state. 
prgUG105G PrgU is an unknown functional protein. 
 
CspA is a putative cold-shock DNA-binding domain protein. 
EFE19808.1 encodes a YdcF-like hypothetical cytidylyltransferase 
family protein. 
S613_D18A10 
liaFΔI177 LiaFΔI177 is supposed to keep LiaFSR pathway in ‘on’ state. 
xpaCK163fs XpaC is a 5‑bromo‑4‑chloroindolyl phosphate hydrolysis protein. 
dacAE554K DacA is D‑alanyl‑D‑alanine carboxypeptidase. 
prgUN103N PrgU is an unknown functional protein. 
 
CspA is a putative cold-shock DNA-binding domain protein. 
EFE19808.1 encodes a hypothetical cytidylyltransferase family 
protein. 
 
EFE19513.1 encodes a putative a putative ABC transporter or a 
putative permease. 
EFE19514.1 encodes a hypothetical protein. 
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Efc S613_D18A10 has a very high intracellular c-di-AMP level (1493±61 
pM/OD600), which is 2-fold higher than S613_D17C9 (735±118 pM/OD600, p=0.002) 
(Figure 4.4A, Table 3.1). By comparing their genotypes, it is likely that xpaC, 
encoding a 5-bromo-4-chloroindolyl phosphate hydrolysis protein, may be the main 
reason. XpaC is annotated as having activity against 5-bromo-4-chloroindolyl 
phosphate but the actual in vivo substrate remains entirely unknown. The 
physiological function of XpaC is also unclear. XpaC may be a c-di-AMP 
phosphodiesterase, so the frame shift mutant (XpaC1-163fs) may abolish or decrease 
its phosphodiesterase activity, leading to the increased c-di-AMP levels observed in 
Efc S613_D18A10 compared with Efc S613_D17C9. 
4.4.2. XpaC is under direct LiaR regulation. 
As mentioned in Section 4.2.1, deletion of liaR results in increased c-di-AMP 
concentrations. If xpaC is a c-di-AMP phosphodiesterase under LiaR regulation, XpaC 
expression should be down-regulated in liaR deficient strains. Indeed, as Figure 4.2B 
shows, xpaC transcription is significantly decreased in Efc OG1RF_ΔliaR, which 
agrees with my hypothesis. 
To further investigate the relationship between LiaR and XpaC, I wanted to 
know how activated LiaR regulates xpaC. As DAP-induced cell membrane stress can 
‘turn on’ the LiaFSR pathway, I incubated Efc S613 with DAP, and analyzed gene 
expression by qPCR. As expected, the LiaFSR pathway was activated by DAP 
exposure, and upregulated liaFSR and liaXYZ (Figure 4.5A). However, the activated 
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LiaFSR regulon only upregulated xpaC, but not other putative c-di-AMP synthases 
and phosphodiesterases (Figure 4.5A). Similar trends were also observed in Efc 
OG1RF (Figure 4.5B). I also identified a putative consensus motif in the upstream 
region of xpaC for that further corroborate my observation that xpaC is directly 
regulated by LiaR (Davlieva et al., 2015a). 
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Figure 4.5 Quantitative PCR shows xpaC is under LiaR regulation in E. faecalis. qPCR results show the gene expression in 
Efc S163 and Efc OG1RF during daptomycin exposure. daptomycin activates LiaFSR pathway, and upregulates LiaFSR and LiaXYZ, 
as well as the putative c-di-AMP phosphodiesterase XpaC. Gene transcript levels of gdpP (coding c-di-AMP phosphodiesterase), 
pgpH (coding a putative c-di-AMP phosphodiesterase), cdaA (coding c-di-AMP synthase A, CdaA), cdaR (coding CdaR, a regulator 
of CdaA) did not change significantly under daptomycin stress (Abranches et al., 2009; Huynh et al., 2015; Rismondo et al., 2016, 
2016). Each measurement was made from at least three independent biological measurements. 
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Figure 4.6 LiaR consensus sequence in the upstream of xpaC. Putative LiaR 
consensus sequence (-105, -90) in the upstream of xpaC in Efc S613. The consensus 
sequences are highlighted in yellow. The gene start codons are highlighted in green. 
 
4.4.3. Current studies to elucidate Xpac structure and function. 
To study the function and structure of XpaC, I attempted to clone Efc Xpac, 
the DAP adaptive mutant Efc XpaCK163fs and XpaC homologs from other Gram-
positive organisms to inducible expression vectors pET-28a (for expression in E. coli) 
and pMSP3535 (for expression in Efc OG1RF).  
In the first stage of molecular cloning, I made 30 different constructs (Table 
4.2), and used E. coli DH5α to select ligation products. After several trials, only 4 
constructs of Efc Xpac with N-terminal 6xHis-tag were successfully generated 
(Construct #1-4 in Table 4.2). Although colony PCR showed positive results for 
other constructs, E. coli lost the recombinant plasmid or the insert during overnight 
incubation. Expression of Constructs #1-4 could be induced in E. coli BL21, but the 
BL21 strains carrying the recombinant plasmids grew much slower than wild type 
BL21 even before IPTG was added to induce expression. These observations suggest 
even leaky expression of XpaC is very toxic for E coli.  
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Genes coding xpaC have only be identified in Gram-positive organisms, such 
as enterococci and staphylococci, suggesting Xpac is not toxic to Gram-positive 
bacteria. B. subtilis is a well-studied model organism, uses c-di-AMP as second 
messenger as well, and does not have xpaC in its genome, which makes it a 
potentially good host to over-express XpaC for functional studies (Oppenheimer-
Shaanan et al., 2011a). My future work is to over express XpaC in B. subtilis. If XpaC 
does have c-di-AMP phosphodiesterase activity, I should be able to observe 
decreased c-di-AMP levels with XpaC overexpression. 
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Table 4.2 Summary of XpaC constructs made in this study. 
# 
Source 
Bacteria 
Constructb Vector 6xHis-tag 
TEV cleavage site 
[Y/N] 
1 Efc S613 XpaC pET-28a N-terminal N 
2 Efc S613 XpaC pET-28a N-terminal Y 
3 Efc S613 XpaCK163fs pET-28a N-terminal N 
4 Efc S613 XpaCK163fs pET-28a N-terminal Y 
5 Efc S613 XpaC pET-28a C-terminal N 
6 Efc S613 XpaCK163fs pET-28a C-terminal N 
7 Efc S613 XpaC 
pMSP35
35 
No tag N 
8 Efc S613 XpaC 
pMSP35
35 
N-terminal N 
9 Efc S613 XpaC 
pMSP35
35 
N-terminal Y 
10 Efc S613 XpaC 
pMSP35
35 
C-terminal N 
11 Efc S613 XpaC 
pMSP35
35 
C-terminal Y 
12 Efc S613 XpaC1-163 
pMSP35
35 
No tag N 
13 Efc S613 XpaC1-163 
pMSP35
35 
N-terminal N 
14 Efc S613 XpaC1-163 
pMSP35
35 
N-terminal Y 
15 Efc S613 XpaC1-163 
pMSP35
35 
C-terminal N 
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16 Efc S613 XpaC1-163 
pMSP35
35 
C-terminal Y 
17 Efc S613 XpaCE163fs 
pMSP35
35 
No tag N 
18 Efc S613 XpaCK163fs 
pMSP35
35 
N-terminal N 
19 Efc S613 XpaCK163fs 
pMSP35
35 
N-terminal Y 
20 Efc TX1467 XpaC pET-28a N-terminal Y 
21 Efc TX1467 XpaC pET-28a N-terminal N 
22 Efc TX1467 XpaC pET-28a C-terminal N 
23 Efc TX1467 XpaCK163fs pET-28a N-terminal Y 
24 Efc TX1467 XpaCK163fs pET-28a N-terminal N 
25 Efc TX1467 XpaCK163fs pET-28a C-terminal N 
26 
Efm 
HOU503 
XpaC pET-28a N-terminal Y 
27 
Efm 
HOU503 
XpaC pET-28a C-terminal N 
28 MRSA 131a XpaC pET-28a N-terminal Y 
29 MRSA 131a XpaC pET-28a N-terminal N 
30 MRSA 131a XpaC pET-28a C-terminal N 
aMRSA 131: Methicillin-resistant Staphylococcus aureus MRSA131. 
bXpaC constructs: the frameshift (AAAC) deletion in XpaC generates a -RMKN tail 
after residue lysine 163. The construct XpaC1-163 only covers the first 163 residues. 
The construct XpaCK163fs covers the following -RMKN tail. 
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4.5. Discussion. 
Since GdpPI440S was identified in association with changes within the LiaFSR 
pathway, I tested the effect of the mutations in LiaFSR pathway upon in vivo c-di-
AMP levels. I found that the deletion of liaR (Efc OG1RF_ΔliaR) led to increased c-di-
AMP levels (Table 3.1 and Figure 4.1) and I observed a significant decrease in c-di-
AMP levels in strains with liaYZ deletions (Figure 4.3). 
While it is tempting to link c-di-AMP levels to LiaFSR signaling, the nature of 
this association is unclear. My qPCR data shows that the transcription of potential 
target genes cdaA, gdpP and pgpH were not altered in LiaR deletion strains (Figure 
4.2), suggesting that the effects of mutations in LiaFSR signaling on cellular c-di-
AMP levels are indirect. It is possible that cellular c-di-AMP pools will also respond 
dynamically through several stress regulons including LiaFSR. In addition, an 
unknown cofactor or stress may switch the function of GdpP from c-di-AMP 
phosphodiesterase (DHH/DHHA1 domain activity) to c-di-AMP synthase (putative 
GGDEF activity) (Hallberg et al., 2016). While I was unable to demonstrate that the 
Efc GdpP GGDEF domain had c-di-AMP synthase activity in vitro, GGDEF domains of 
other proteins do have demonstrated synthase activity (Hallberg et al., 2016). How 
the PAS domain of GdpP might regulate the known DHH/DHHA1 domain 
phosphodiesterase activity as well as the potential cryptic activities of the GGDEF 
domain also remains unknown. Additionally, other as yet unidentified regulatory 
mechanisms may also be involved in the system. For example, xpaC is under LiaR 
regulation (Figure 4.5), and the mutant xpaCK163fs was identified in Efc S613_D18A10 
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with greatly increased intracellular c-di-AMP levels (Figure 4.4 and Table 3.1), 
suggesting that XpaC is a bone fide c-di-AMP phosphodiesterase and is involved in 
LiaR-mediated cell wall stress response. Although the complete signaling 
mechanism by which LiaFSR regulates c-di-AMP level remains to be fully elucidated, 
it is evident that membrane damage is faithfully transduced and converted into 
altered levels of c-di-AMP. 
In summary, I have shown that c-di-AMP is an important second messenger 
in enterococci. Moreover, LiaFSR and LiaXYZ regulate c-di-AMP pools in vivo at 
physiologically relevant levels and that there is a clear, but indirect, role for the 
LiaFSR regulon. Further, my data shows that although there is no direct linear 
correlation between DAP resistance and c-di-AMP my findings suggest that c-di-
AMP signaling constitutes a key aspect of the membrane damage response with 
important consequences for our understanding of how enterococci respond to DAP 
and other cationic antimicrobial peptides. 
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Chapter 5 
Structural studies of GdpP 
5.1. Structural studies of full-length wild-type Efc GdpP 
Efc GdpP has five domains: two transmembrane motifs on its N-terminus, 
one PAS domain, one GGDEF domain with weak ATPase activity, and one 
DHH/DHHA1 domain with c-di-AMP specific phosphodiesterase activity (Figure 1.1). 
To date, there are no structures for any full-length proteins in this family. A high-
resolution structure of GdpP would be very informative as it would reveal the 
overall domain structure as well as a detailed view of the actives sites responsible 
for its biological activities. Also, any structures solved from crystals grown 
with/without potential cofactors/substrates/products would potentially reveal how 
the activities are regulated, and the molecular mechanism for how GdpP responds 
and controls cyclic dinucleotide signaling. 
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5.1.1. Crystallization of full-length Efc GdpP. 
Efc GdpP with an N-terminal His-tag was over-expressed in E. coli BL21, 
purified by Ni-NTA and gel filtration chromatography (Figure 5.1)  (please see 
Section 2.4 for details). The final yield of Efc GdpP was 0.1 mg/L to 0.2 mg/L, which 
was very low. Since Rao’s group reported that B. subtilis GdpP had a heme-binding 
PAS domain, and the binding of heme helped make this protein more stable, I 
investigated whether the addition of heme might increase protein yield (Rao et al., 
2011). The expression conditions for GdpP were optimized by adding 10µM heme 
with 0.5mM IPTG during induction. The yield of protein was improved by at least 
two times, and 0.4 mg/L to 0.5mg/L protein could be obtained after purification. 
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Figure 5.1 Purification of Efc GdpP. Protein was purified on a Superdex-200 size 
exclusive column (A) and analyzed by SDS-PAGE (B). The numbers correspond to 
elution fractions. M.W.: protein molecular weight ladder. 
 
Efc GdpP was concentrated to A280=10 (11.18 mg/ml) to set up sparse matrix 
screening for crystals. The crystallization conditions for primary screens are 
summarized in Table 5.1. Some small and micro crystals were obtained from 
primary screens. Small crystals could grow in five conditions and were further 
optimized (Table 5.2).  
These five crystallization conditions were manually optimized by varying 
protein concentration, buffer pH, precipitant concentration, drop size, temperature, 
ratio between protein and mother liquor, and vapor diffusion method. Only some 
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small crystals were obtained during the optimization of Condition A (Figure 5.2A). 
And several big crystals were obtained from the optimization of Condition B (Figure 
5.2B), C (Figure 5.2C) and D (Figure 5.2D). Unfortunately, all of them diffracted to 
7.9Å to 12Å. 
Table 5.1 Summary crystallization conditions for primary screens. 
Catalog No. Crystal Screen Kit Temperature 
Hampton HR2-130 Crystal Screen HT 
4°C, 10°C, 20°C 
Hampton HR2-134 Index HT  
Hampton HR2-136 SaltRx HT 
QIAGEN 130901 Classics Suits 
QIAGEN 130904 PEGs Suits 
QIAGEN 130905 AmSO4 Suits 
QIAGEN 130906 MPD Suite 
QIAGEN 130907 Anion Suits 
QIAGEN 130909 pHClear Suite 
QIAGEN 130910 pHClear II Suite 
QIAGEN 130911 MbClass Suite 
QIAGEN 130912 MbClass II Suite 
QIAGEN 130916 PEGs II Suite 
QIAGEN 130920 JCSG+ Suits 
QIAGEN 130923 Classics II Suite 
 
 
Table 5.2 Efc GdpP crystallization conditions for optimization. 
# Crystallization Condition Temperature 
A 3.5M Sodium formate pH7.0. 10°C 
B 1.0M Succinic acid pH 7.0, 0.1M HEPES pH 7.0, 1% w/v PEG 
2000 
10°C 
C 35% v/v Tacsimate pH7.0 10°C 
D 0.2M Magnesium Chloride, 0.1M HEPES Sodium Salt pH7.5, 
30% (v/v) PEG 400 
10°C 
E 0.2M Magnesium acetate, 0.1M Sodium cacodylate pH6.5, 
20% (w/v) PEG 8000. 
10°C 
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Figure 5.2 Crystals of full-length wild-type Efc GdpP grew in optimized 
conditions. (A) Crystals grew in: 3.5M sodium formate pH7.0; (B) 1.15M succinic acid 
pH6.5, 0.1M HEPES pH6.5, 1% (w/v) PEG 2000 at 10°C; (C) 32% (v/v) tacsimate pH7.0 
at 10°C; (D) and 0.1M magnesium chloride, 0.1M HEPES sodium salt pH7.0, 20% (v/v) 
PEG 400 at 10°C. 
 
The two crystals grown in Condition E (Table 5.2) in primary screens 
diffracted to 3.5 Å and 5Å (Figure 5.3A). But in the following optimizations, crystals 
would not grow spontaneously and so trays were set up by micro seeding using a 
seed bead kit (Hampton HR2-320) to establish reproducible crystal growth. 
Additive Screen (Hampton HR2-428), Silver Bullets Bio HT (Hampton HR2-088), 
and Detergent Screen HT (Hampton HR2-406) were also screened to optimize 
crystallization. Since Efc GdpP has ATPase and c-di-AMP specific phosphodiesterase 
100 
 
activities, its substrates (ATP and c-di-AMP), products (ADP and 5’pApA), inhibitors 
(AMPPNP and ppGpp), and other adenosine derivatives (such as AMP and cAMP) 
were also tried as additives to optimize this condition. The putative PAS domain 
cofactors, such as heme, bilirubin and biliverdin, were also screened. Several big 
crystals were obtained with ADP as an additive (Figure 5.3B).  
Crystals were mounted and frozen with in cryo buffer optimized using 
Hampton Research Crystal Screen Cryo (HR2-122). The optimal cryo buffer contains 
70% mother liquor (v/v) and 30% glycerol (v/v). Crystals were sent to Advanced 
Photon Source Synchrotron, and data were collected with beamline 21-TD-D. The 
best crystal diffracted to 3.3Å (Figure 5.3C and Table 5.3). Data was collected with 
250mm distance, 1 degree oscillation angle and 1s exposure time. 
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Figure 5.3 Crystals of Efc GdpP. (A) Before optimization: crystals grown in 0.2M 
magnesium acetate, 0.1M sodium cacodylate pH6.5, and 20% (w/v) PEG 8000 at 10°C. 
(B) After optimization: Crystal grown in 0.2M magnesium acetate, 0.1M sodium 
cacodylate pH 6.5, 5% PEG8000, and 675µM ADP at 10°C. (C) Figure shows the 
diffraction of Efc GdpP crystal. 
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Table 5.3 Data collection statistics of wild type full-length Efc GdpP. 
Parameter  
Space group P1 
Unit cell parameters 
a, b, c (Å) 
α, ß, γ (°) 
 
114.03, 147.33, 164.83 
86.58, 79.95, 89.01 
Resolution limits (Å) 40.0-3.30 (3.36-3.30) 
Total number of observations 608,957 
Number of unique reflections 155,170 
I/ σI 7.4 (2.77) 
Completeness (%) 98.9 (98.3) 
Rmerge (%) 9.6 (85.2) 
 
 
HKL2000 was used to index the data set. The crystal had low symmetry, and 
can only be indexed under P1 space group (Table 5.3). The average Rmerge was 9.6%. 
The Rmerge for the highest resolution shell 3.36Å-3.30Å is 0.852 (Table 5.4). The 
completeness is higher than 98% (Table 5.5). The redundancies are higher than 3.8 
(Table 5.6).  
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Table 5.4 Summary of reflections intensities and R-factors by shells. 
 
  
104 
 
Table 5.5 Summary of the completeness by shells. 
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Table 5.6 Summary of redundancies by shells. 
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5.1.2. Crystallization of selenomethionine Efc GdpP. 
To obtain the phases for structure determination, I prepared 
selenomethionine (Se-Met) Efc GdpP by replacing the Met by Se-Met for single-
wavelength anomalous dispersion (MAD). There are 20 methionines in Efc GdpP. To 
prepare Set-Met Efc GdpP, protein was expressed in minimal medium with Se-Met 
and other amino acids supplied, and purified using the same protocols as the wild 
type (Figure 5.4 A, B). Large scale crystal screens were set up using Se-Met 
containing protein. The Se-Met Efc GdpP crystals with best diffraction were grown 
in the same conditions as the wild-type Efc GdpP (0.2M magnesium acetate, 0.1M 
sodium cacodylate pH 6.5, 5% PEG8000, and 675µM ADP), and diffracted to 8Å 
(Figure 5.4C).  
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Figure 5.4 Purification and crystallization of Se-Met Efc GdpP. Se-Met Efc GdpP 
was purified on a Superdex-200 size exclusive column (A) and analyzed by SDS-PAGE 
(B). The numbers correspond to elution fractions. M.W.: protein molecular weight 
ladder. (C) Se-Met Efc GdpP crystals grown in 0.2M magnesium acetate, 0.1M sodium 
cacodylate pH 6.5, 5% PEG8000, and 675µM ADP at 10°C. (D) Se-Met Efc GdpP crystals 
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grown in 0.24M magnesium acetate, 0.1M sodium cacodylate pH6.5, 4% PEG8000, 
6.5% pluronic F-68, and 675µM ADP at 10°C. 
 
To further optimize Se-Met Efc GdpP crystals, I set up trays and varied buffer 
pH, protein concentration, precipitant concentration, and ratios between Se-Met Efc 
GdpP and ADP. I screened chemical reagents from Detergent Screen (Hampton HR2-
408), Additive Screen HT (Hampton HR2-138), and Silver Bullet (Hampton HR2-
088). I found that pluronic F-68 improved diffractions the most to 3.8Å (Figure 
5.4D). However single crystals did not grow in this condition, so I broke the crystal 
cluster and mounted single crystals for data collection. Resolution of Se-Met Efc 
GdpP crystal was not high enough for phase determination. 
To further optimize the diffraction, I prepared Se-Met Efc GdpP with lysine 
methylation as described in (Kim et al., 2008) (Figure 5.5). Reductive methylation of 
the solvent exposed lysine residues in protein can reduce their chains flexibilities 
(Kim et al., 2008). So lysine methylation may change protein properties and improve 
the molecular packing in crystals, which improves crystal diffractions (Kim et al., 
2008). Sparse matrix screens were set up using Hampton Research kits listed in 
Table 5.1. Crystals were observed in 16 conditions, but none of them diffracted. 
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Figure 5.5 Purification of Se-Met Efc GdpP with lysine methylation. Protein was 
purified on a Superdex-200 size exclusive column (A) and analyzed by SDS-PAGE (B). 
The numbers correspond to elution fractions. M.W.: protein molecular weight ladder. 
 
5.1.3. Heavy atom screening for multiple isomorphous replacement (MIR) 
When suitable electron-dense heavy atoms bind to proteins, the scattered 
intensity of protein crystals will change significantly (Boggon and Shapiro, 2000). So 
the scattering of heavy atoms can be used to determine crystallographic phases. To 
find heavy atom compounds that can bind to Efc GdpP, I incubated the candidate 
compound with Efc GdpP, and analyzed the binding by native PAGE (Boggon and 
Shapiro, 2000). Protein properties such as net charge will change if heavy atoms are 
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bound, which usually causes a band shift in native PAGE. As shown in Figure 5.6, the 
native gel result suggests that C7H5ClHgO2 bound to Efc GdpP, but HoCl3•6H2O and 
NdCl3•xH2O did not. K2HgI4 caused extensive precipitation of Efc GdpP. In total, 65 
heavy atom reagents from heavy atom screening kits (Hampton Research HR2-442, 
HR2-446, HR2-448, HR2-450) were analyzed by this method. Nine compounds gave 
positive results and did not cause protein precipitation (Table 5.7). These nine 
compounds were used to do crystal heavy atom soaking.  
Efc GdpP crystals were grown in 0.2M magnesium acetate, 0.1M sodium 
cacodylate pH 6.5, 5% PEG8000, and 675µM ADP. Crystals were soaked in crystal 
mother liquor with 1mM to 10mM heavy atom compounds for 10min, 1hr, 2hr or 
overnight at 10˚C or room temperature before being frozen. Fluorescence scans 
suggested that heavy atoms bound to the proteins. The Efc GdpP crystals usually 
diffracted to 3Å to 5Å, but after soaking, their diffractions dropped below 8Å. The 
heavy atom reagents appear to disrupt crystal order even at low concentration and 
with shortened soaking times. 
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Figure 5.6 Native PAGE gel result of derivatization analysis. 2µL of 2mg/mL Efc 
GdpP was incubated with 2µL of 10mM heavy atom reagent solution on ice for 10min. 
Samples were analyzed by 10% native PAGE gel (Boggon and Shapiro, 2000). HoCl3•
6H2O: Holmium(III) chloride hexahydrate. NdCl3•xH2O: Neodymium(III) chloride 
hydrate. C7H5ClHgO2: p-Chloromercuribenzoic acid. K2HgI4: Mercury(II) potassium 
iodide. All compounds are from Hampton Research. 
 
Table 5.7 Compounds used for heavy atom soaking. 
Heavy atom compounds Chemical formula 1Catalog No. 
Potassium hexachloroplatinate 
(IV) K2PtCl6 HR2-442-3 
Potassium tetranitroplatinate (II) K2Pt(NO2)4 HR2-442-4 
Phenylmercury acetate C8H8HgO2 HR2-446-6 
p-chloromercuribenzoic acid C7H5ClHgO2 HR2-446-8 
Lead (II) acetate trihydrate Pb(CH3COO)2 • 3H2O HR2-448-4 
Lead (II) nitrate Pb(NO3)2 HR2-448-5 
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Lead (II) chloride PbCl2 HR2-448-6 
Cadmium chloride hydrate CdCl2.xH2O HR2-448-8 
Sodium phosphotungstate Na3[P(W3O10)4].aq HR2-450-19 
1All compounds are from Hampton Research.  
5.1.4. Post-crystallization optimization of wild-type Efc GdpP and Se-Met Efc 
GdpP. 
5.1.4.1. Crystal dehydration 
Crystal dehydration is a post-crystallization treatment to tighten the packing 
of protein molecules in the crystals by removing excess water and sometimes 
improves crystal diffraction (Heras and Martin, 2005).  
Wild-type Efc GdpP Crystals and Se-Met Efc GdpP crystals were grown in 
three conditions including: (1) 27%~38% (v/v) tacsimate pH7.0; (2) 0.1M 
magnesium chloride, 0.1M HEPES sodium salt pH7.0, 15% to 26% (v/v) PEG 400; 
and (3) 0.2M magnesium acetate, 0.1M sodium cacodylate pH 6.5, 675μM ADP, 2% 
to 7% PEG8000. Crystals were soaked in the solution containing 5%-30% higher 
concentrations of precipitants for 30min to 1hr before being frozen (Heras and 
Martin, 2005).  However, these dehydration-treated crystals diffracted more poorly 
from 8Å to 20Å. 
5.1.4.2. Crystal annealing 
Although cryoprotection is effective to protect protein crystals from 
radiation damage, uneven flash-cooling can increase crystal mosaicity and reduce 
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diffraction resolution (Harp et al., 1998). To avoid this problem, I performed crystal 
annealing by blocking the cryostream to warm the crystals to room temperature, 
and flash-cooling it again (Harp et al., 1998) but again crystal annealing decreased 
Efc GdpP crystal diffractions to 20Å. 
5.2. Structural studies of Efc GdpPI440S 
The Efc GdpPI440S was identified in several experimental DAP-resistant 
strains (Miller et al., 2013). The I440S mutation is located in GdpP DHH/DHHA1 
domain (Figure 1.1). I have shown that I440S mutation significantly decreases GdpP 
phosphodiesterase activity, and can induce intracellular c-di-AMP accumulation 
(please see section 3.3.2 for details). 
To study how the I440S mutation changes GdpP structure, Efc GdpPI440S was 
expressed and purified in the same way as wild-type Efc GdpP (Figure 5.7 A and B). 
Sparse matrix screens were set up using 11.18mg/ml Efc GdpPI440S. Wild-type Efc 
GdpP crystals were also broken and used as micro seeds to induce Efc GdpPI440S 
crystal growth.  
The crystals diffracted best to 3.3Å, and were grown in 0.2M magnesium 
acetate, 0.1M sodium cacodylate pH 6.5, 5% PEG8000 (Figure 5.7C). 
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Figure 5.7 Purification and crystallization of Efc GdpPI440S. Protein was purified 
on a Superdex-200 size exclusive column (A) and analyzed by SDS PAGE (B). The 
numbers correspond to elution fractions. M.W.: protein molecular weight ladder. (C) 
Crystals grew in 0.2M magnesium acetate, 0.1M sodium cacodylate pH7.0, 5% (w/v) 
PEG 8000 at 10°C. 
5.3. Structural studies of Efc GdpPD419A and Efc GdpPD419A/D499A 
As discussed in Session 3.3.1.5, Asp419 and Asp499 in Efc GdpP DHH/DHHA1 
domain are predicted to interact with divalent cations required for 
phosphodiesterase activity (Figure 3.7) (Corrigan et al., 2011; Rao et al., 2010). 
Since double mutations D429A/D499A completely abolished Efc GdpP 
phosphodiesterase activity (Figure 3.3), co-crystallization of c-di-AMP and Efc GdpP 
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mutants (Efc GdpPD419A and Efc GdpPD419A/D499A) may stabilize or reduce the 
conformational dynamics of the GdpP structure and improve the quality of crystals.  
Efc GdpPD419A and Efc GdpPD419A/D499A were overexpressed in E. coli BL21 and 
purified using the same purification protocols of wild-type Efc GdpP (Figure 5.8 A-
D). Sparse matrix screens were set up using the kits listed in Table 5.1 with or 
without c-di-AMP as additives. Crystals were grown in similar conditions to wild-
type GdpP (Figure 5.8 E-I). After optimization, Efc GdpPD419A crystals only diffracted 
to 8Å ~10Å. Efc GdpPD419A/D499A crystals diffracted best to 3.3Å, and were grown in 
0.2M magnesium acetate, 0.1M sodium cacodylate pH6.5, 7% PEG8000, 270µM c-di-
AMP (Figure 5.8H). 
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Figure 5.8 Purification and crystallization of Efc GdpPD419A and Efc 
GdpPD419A/D499A. Efc GdpPD419A was purified on a Superdex-200 size exclusive column 
(A) and analyzed by SDS PAGE (B). Efc GdpPD419A/D499A was purified on a Superdex-200 
size exclusive column (C) and analyzed by SDS PAGE (D). The numbers correspond to 
elution fractions. M.W.: protein molecular weight ladder. (E-G): Efc GdpPD419A crystals 
grew in (E): 0.2M magnesium acetate, 0.1M sodium cacodylate pH6.5, 5% PEG8000, 
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and 405µM c-di-AMP at 10°C; (F) 0.1M magnesium chloride, 0.1M HEPES pH7.0, 18% 
PEG4000, and 270µM c-di-AMP at 10°C; (G) 30% tacsimate pH7.0, and 270µM c-di-
AMP at 10°C. (H-I): Efc GdpPD419A/D499A crystals grew in (H) 0.2M magnesium acetate, 
0.1M sodium cacodylate pH6.5, 7% PEG8000, 270µM c-di-AMP at 10°C; (I) 0.1M 
magnesium chloride, 0.1M HEPES pH7.0, 20%PEG4000, and 270µM c-di-AMP at 10°C. 
 
5.4. Structural studies of Efc GdpP truncations. 
5.4.1. Construct design 
Efc GdpP is a 72kDa molecule with 5 different domains. GdpP truncations 
with fewer domains may reduce protein flexibility and produce better crystals. To 
identify the flexible region in GdpP for truncation, I performed limited proteolysis 
by trypsin and chymotrypsin (Fontana et al., 2004). I optimized the reactions by 
trying different temperatures, incubation times, and ratios between protein and 
proteases. However, no clear limit product band could be observed by SDS-PAGE.  
I analyzed Efc GdpP protein sequence and aligned it to other GdpP homologs 
that have been studied (Figure 3.2, Figure 3.10) (Cho and Kang, 2013; Corrigan et al., 
2011; He et al., 2015; Rao et al., 2010; Smith et al., 2012). I also used the Phyre2 
server to predict Efc GdpP secondary structure. Truncations were designed to avoid 
disrupting rigid secondary structures. Nine constructs were made for structural 
studies (Table 5.8). 
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Table 5.8 Summary of structural studies of E. faecalis GdpP. 
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5.4.2. Efc GdpP with C-terminal His-tag 
Full-length Efc GdpP with a C-terminal 6xHis-tag was constructed. Since C-
His Efc GdpP was soluble, it was expected that the His-tag could be removed from C-
terminal to make crystallization of no-tag protein possible. 
C-His Efc GdpP was overexpressed in 10L 2xYT medium, and was first 
purified on a Ni-NTA column, and then on a Superdex-200 size exclusion column. 
The expression of C-His Efc GdpP was not good even after optimization. Only 2mg of 
protein was purified from 10 liters of cells using this modest 2-step purification. 
Additionally, the protein purity was lower than 30% than I had obtained from 
earlier purification of the full-length protein (Figure 5.9). 
 
Figure 5.9 Purification of Efc GdpP with C-terminal His-tag. (A) purification of C-
His Efc GdpP on a Superdex-200 size exclusion column. (B) SDS-PAGE analysis of gel 
120 
 
filtration purification. The numbers correspond to elution fractions. M.W.: protein 
molecular weight ladder. 
 
5.4.3. GGDEF domain truncation Efc GdpP167-300 
Efc GdpP167-300 includes the GdpP GGDEF domain (Table 5.8), and is 
predicted to be ~17kDa. Efc GdpP167-300 could not be expressed despite a trying 
several optimization strategies such as varying temperatures (16°C, 28°C, and 37°C) 
and media conditions (2xYT and EnPressoTM media (BioSilta)). I was unable to 
obtain enough soluble protein for sparse matrix trials. 
5.4.4. PAS domain truncation Efc GdpP82-159 and DHH/DHHA1 domain 
truncation Efc GdpP332-658  
Efc GdpP82-159 is the PAS domain (Table 5.8). Efc GdpP332-658 is a construct 
that encodes the DHH/DHHA1 domain (Table 5.8). Both could be overexpressed in E. 
coli BL21, but were not soluble and thus no further crystallization studies were 
performed. 
5.4.5. GGDEF-DHH/DHHA1 domain truncation Efc GdpP167-658 with N-terminal 
or C-terminal His-tag 
Efc GdpP167-658 constructs could be expressed, and both were soluble. The 
molecular weight of Efc GdpP167-658 with His-tag is 56kDa.  
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N-His Efc GdpP167-658 was first purified on Ni-NTA column, followed with a 
Superdex-200 size exclusion column. After gel filtration, the purity of Efc GdpP167-658 
was lower than 60% with a large amount of contaminants (60kDa-75kDa, and 
40kDa) co-purified (Figure 5.10A). I could not optimize sufficient yields of protein 
with sufficient purity for crystallization trials.  
C-His Efc GdpP167-658 was purified first on Ni-NTA. A large amount of lower-
molecular-weight contaminants (40kDa) were co-purified (Figure 5.10B). This 
construct was very unstable and rapidly degraded and then precipitated after 
purification making it a poor candidate for crystallographic screens.  
Different protein purification I tried a variety of columns and strategies were 
tested to remove contaminants, including Q-sepharose column (anion exchange), 
SP-sepharose column (cation exchange), hydrophobic interaction chromatography 
(HIC) column, and optimizing purification buffers. However, none of these 
approaches produced satisfactory results and all these aforementioned constructs 
proved insufficient for crystallographic trials. 
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Figure 5.10 Efc GdpP167-658 was co-purified with contaminants. (A) N-His Efc 
GdpP167-658 was purified on a Superdex-200 size exclusive column. The numbers 
correspond to elution fractions. N-His Efc GdpP167-658 was mainly eluted in peak one 
(fraction #19 and #20) with contaminates. (B) C-His Efc GdpP167-658 was purified on 
Ni-NTA column but had a large amount of contaminants. M.W.: protein molecular 
weight ladder. 
123 
 
5.4.6. PAS-GGDEF-DHH/DHHA1 domain truncation Efc GdpP56-658 
Efc GdpP56-658 is the truncation that includes the PAS-GGDEF-DHH/DHHA1 
domains (Table 5.8). Efc GdpP56-658 was purified using the same protocols as full-
length Efc GdpP but unfortunately the yield was low. Only 0.5mg protein could be 
purified from 8L of cell culture (Figure 5.11 A and B). Sparse matrix screens were 
set up using 11.42mg/ml protein in the conditions listed in Table 5.1. Crystals only 
grew in one condition, and did not diffract beyond the beam stop at the synchrotron 
(Figure 5.11C). 
 
Figure 5.11 Purification and crystallization of Efc GdpP56-658. (A-B) Purification 
of Efc GdpP56-658 on a Superdex-200 size exclusive column. SDS-PAGE analysis shows 
protein purity. The numbers correspond to elution fractions. Fraction #27-#29 were 
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collected for crystallization. M.W.: protein molecular weight ladder. (C) Crystals grew 
in 0.1M tris pH8.5, 2.0M ammonium phosphate at 10°C. 
 
5.4.7. DHH/DHHA1 domain truncation Efc GdpP309-658 and Efc GdpP ۷૝૝૙܁૜૙ૢ − ૟૞ૡ 
Efc GdpP309-658 contains the DHH/DHHA1 domain, with a longer N-terminal 
flexible tail than Efc GdpP332-658 (Table 5.8). Efc GdpP I440S309 − 658 could not be expressed 
in E. coli BL21 despite attempts at optimization by varying temperature and media. 
Wild-type Efc GdpP309-658 could be overexpressed in 2xYT media at 37 °C.  
Efc GdpP309-658 was purified by Ni-NTA affinity chromatography, anion 
exchange and gel filtration chromatography (Figure 5.12 A and B). Around 7mg 
protein could be purified from 5L culture. Sparse matrix crystal screening was set 
up using conditions listed in Table 5.1. Some small and micro crystals were obtained 
from primary screenings. Crystals grown in 2 conditions showed weak diffraction, 
and were further optimized (Figure 5.11 C and D). 
In primary screening, the crystals grown in 4M sodium formate were cubic, 
and diffracted to 8Å (Figure 5.12C). This condition was optimized by using different 
concentrations of sodium formate and protein, different drop sizes, different ratios 
between protein and mother liquor, different temperatures, and setting up hanging 
drops and sitting drops. However, the cubic crystals could not be reproduced even 
using the earlier cubic crystals as seeds. The new crystals grown in 2.5M sodium 
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formate formed clusters of needles, and only diffracted to 20 Å (Figure 5.12E). I 
have been unable to reproduce the original crystals. 
Efc GdpP309-658 crystals grown in 0.1M MgCl2, 0.05M HEPES pH7.5, 15% (w/v) 
PEG 2000 diffracted to 5 Å (Figure 5.12D). After optimization, bigger crystals were 
generated (Figure 5.12F). But none of them showed better diffraction. 
 
Figure 5.12 Purification and crystallization of Efc GdpP309-658. Efc GdpP309-658 
was purified on a Superdex-200 size exclusive column (A) and analyzed by SDS-
PAGE (B). Crystals grew in (C) 4M sodium formate at 10°C; (D) 2.5M sodium formate 
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at 10°C; (E) 0.1M MgCl2, 0.05M HEPES pH7.5, 15% (w/v) PEG 2000 at 10°C; (F) 0.1M 
MgCl2, 0.1M HEPES pH7.5, 7% (w/v) PEG 2000 at 10°C. 
 
5.5. Structural studies of Efm GdpP 
Since Efc GdpP and its truncations did not behave well for crystallography, 
constructs of E. faecium R494 GdpP (Efm GdpP) and its variants were also made. 
Efm GdpP is a homolog of EfsGdpP with 58% identity at the level of amino acid 
sequence. Protein blast showed there was no strong homology between Efm GdpP 
and other PAS domains. I aligned Efm GdpP sequence to B. subtilis GdpP to predict a 
putative PAS domain. However, the PAS region predicted by alignment to Bs GdpP 
overlapped with the GGDEF domain predicted by protein blast, suggesting Efm GdpP 
does not have a PAS domain or that it is very different than canonical PAS domains 
(Figure 5.13). 
 
Figure 5.13 Domain organization of E. faecium  R494 GdpP. Efm GdpP is a multi-
domain protein containing two putative N-terminal transmembrane helices, a GGDEF 
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domain and a DHH domain with a DHHA1 subdomain. The PAS domain predicted by 
alignment to B. subtilis GdpP overlaps with the GGDEF domain predicted by protein 
blast, suggesting Efm GdpP may not have a canonical PAS domain.   
 
Seven constructs were made with N-terminal 6xHis tag (Table 5.9), including 
full-length Efm GdpP, Efm GdpP83-657, Efm GdpP137-657, Efm GdpP338-657, Efm GdpP338-
500, Efm GdpP137-298, and Efm GdpP83-167. The full-length Efm GdpP, Efm GdpP338-657, 
and Efm GdpP137-298 could be expressed, but were not soluble. Efm GdpP83-657, Efm 
GdpP137-657, Efm GdpP338-500, and Efm GdpP83-167 could not be expressed even after 
optimization. 
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Table 5.9 Summary of structural studies of E. faecium GdpP. 
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5.6. Discussion and Future work 
The Efc GdpP309-658 crystals are under optimization. We found the detergent 
fluorinated octyl maltoside could dramatically increase Efc GdpP309-658 
phosphodiesterase activity (please see Session 3.3.1 for details). Fluorinated octyl 
maltoside will be used for further crystallization optimization together with additive 
screen kits and Silver Bullet kit.  
Additionally, iodide derivatives will be tried with quick soaking to try and 
obtain phases for the full-length Efc GdpP crystals. An Efc GdpP structure will reveal 
the active site of phosphodiesterase, binding pocket of cyclic-dinucleotide and 
inhibitor ppGpp and is clearly a very valuable structure for understanding GdpP 
function. The structures solved from Efc GdpP and Efc GdpPD419/D499A crystals grown 
with/without potential cofactors/substrates/products will reveal how the activity is 
regulated, and the molecular mechanism of how GdpP responds and controls cyclic 
dinucleotide signaling. 
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Chapter 6 
Conclusions and Future Studies 
6.1. Discussion 
Multidrug-resistant pathogen infections have become serious threats to 
public health (CDC, 2013). In the United States, 66,000 people get enterococcus 
infections each year, and 30% of the infections are caused by vancomycin-resistant 
enterococcus (VRE) (CDC, 2013). Since VRE is resistant to almost all clinically 
available antibiotics, daptomycin (DAP) is used as the last resort treatment against 
recalcitrant VRE infections (Arias and Murray, 2012). Unfortunately, DAP resistance 
arises during clinical application (Arias and Murray, 2008). To develop efficacious 
therapies for DAP-resistant VRE infections, it’s important to understand the 
biological mechanism behind the resistance. 
In this work, I show for the first time that c-di-AMP is a second messenger in 
enterococci. I also show that Efc GdpP is a c-di-AMP-specific phosphodiesterase, and 
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regulates the intracellular c-di-AMP concentration. The DAP adaptive mutation 
I440S strongly decreases Efc GdpP phosphodiesterase activity. Furthermore, the cell 
stress response module LiaFSR-LiaXYZ interacts c-di-AMP signaling. I also discover 
a novel putative c-di-AMP phosphodiesterase XpaC that is under direct LiaR 
regulation. Additionally, I show my structural studies about Efc GdpP and Efm GdpP. 
6.2. Current and future works 
For the structural studies of Efc GdpP, to solve the phase problem, I will 
perform quick heavy atom soaking using iodide derivatives. My previous heavy 
atom soaking trials show that even 10min soaking of Efc GdpP in heavy atom 
reagents could disrupt crystal diffractions (Section 5.1.3). I so will perform quick 
soaking of 5s to 1min. 
The crystals of Efc GdpP309-658 containing the DHH-DHHA1 domain diffracted 
to 5 Å (Section 5.4.7). Since the c-di-AMP phosphodiesterase assay results suggest 
the detergent fluorinated octyl maltoside can help reducing Efc GdpP309-658 
aggregation (Section 3.3.1.4), I will set up sparse matrix screening of Efc GdpP309-658 
with fluorinated octyl maltoside for crystals. 
I also want to identify the putative cofactors of GdpP. As Efc GdpP over-
expressed in E. coli BL21 showed weak enzyme activities, suggesting Gram-negative 
bacteria E. coli lacks the essential GdpP cofactors. I will over express Efc GdpP in E. 
coli BL21, and purify the protein by Ni-NTA. I will use cell extracts of Efc S613 for a 
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pull-down assay using Ni-NTA chromatography. The cofactors that can bind to GdpP 
will be analyzed by mass spectrometry. 
On the other hand, I discover a putative phosphodiesterase XpaC under 
direct LiaFSR regulation (Section 4.4). Since I Couldn’t over-press this protein in E. 
coli BL21, I will make recombinant plasmids to overexpress XpaC in B. subtilis. I will 
purify XpaC and use HLPC to analyze its function. 
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Appendix A 
In Efc S613_D17C9, the 34bp cspA/EFE19808.1 intergenic deletion may affect 
intracellular c-di-AMP level. 
Efc S613_D17C9 has 3 mutations, liaFΔI177, prgUG105G (with unknown 
function), and a 34bp intergenic deletion between cspA (coding a putative cold-
shock DNA-binding domain protein) and EFE19808.1 (coding a YdcF-like 
hypothetical cytidylyltransferase family protein) (Please see Section 4.4.1 and Table 
4.1 for details). 
To study how activation of LiaFSR pathway (liaFΔI177) affects intracellular c-
di-AMP level, the strain S613_liaFΔI177 was tested (Figure A-1). The c-di-AMP level 
was down-regulated in S613_liaFΔI177 (61.5±81 pM/OD600 versus 113±81 
pM/OD600). But the c-di-AMP level differences between S613_liaFΔI177 and S613 are 
not distinctly different (p=0.329). As S613 strains are not stable, S613_liaFΔI177 
needs be sent for whole genome sequencing to confirm its genotype. 
        On the other hand, very high c-di-AMP levels were observed in 
S613_D17C9 (735±118 pM/OD600) compared with S613 and S613_liaFΔI177 (Table 
3.1 and Figure 4.4). The 34bp intergenic deletion in S613_D17C9 deletes the entire 
putative terminator at the downstream of cspA (Figure A-2.a). To test how Δ34bp 
affects the gene expressions, qPCR was performed (Figure A-2.b). perM is the 
downstream gene of EFE19808.1, coding a putative permease (Figure A-2.a). 
EFE19808.1 and perM are supposed to be in the same operon (Figure A-2.a). With 
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Δ34bp, EFE19808.1 was upregulated by 212.3±26.6 fold (Figure A-2.b). This 
dramatically upregulated EFE19808.1 expression may cause the increased c-di-AMP 
level in S613_D17C9. EFE19808.1 encodes a hypothetical YdcF-like 
cytidylyltransferase family protein. How EFE19808.1 expression affects cellular c-
di-AMP level is still unclear. The transcription of cspA was upregulated by 20.9±4.3 
fold (Figure A-2). The transcription of perM was upregulated by 21.2±5.6 fold 
(Figure A-2). There is a LiaR consensus in the upstream of cspA (-325, -340). So the 
upregulation of cspA may be caused by the activation of LiaFSR pathway in 
S613_D17C9. The other possibility is that the transcription of cspA-EFE19808.1-
perM makes a more stable RNA product than cspA itself, leading to the increased 
transcription of cspA.  
 
Figure A-1 Intracellular c-di-AMP levels in Efc S613_liaFΔI177. The Intracellular c-
di-AMP concentrations were measured by an enzyme-linked immunosorbent assay 
(ELISA) in the absence of daptomycin (Underwood et al., 2014). Mutations that are 
associated with activation of LiaFSR (liaFΔI177) show decreased c-di-AMP 
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concentrations. There are putative additional mutations in S613_liaFΔI177. Each c-di-
AMP measurement was made from at least three independent biological 
measurements. 
 
 
Figure A-2 Quantitative PCR results show gene expression fold change in E. 
faecalis S613_D17C9. (a) Genetic organization in the 34bp intergenic deletion region. 
The predicted terminator hairpin is shown in the figure. Please see Table 4.1 for gene 
descriptions. (B) Quantitative PCR results of cspA, EFE19808.1, and perM in S613 and 
S613_D17C9. Please see Table 4.1 for gene descriptions.  
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 Appendix B 
Growth rates of Efc S613 and Efc S613_D17C9. 
To examine the growth rates of Efc S613 and Efc S613_D17C9 (Table 3.1 and 
Table 4.1), the relative amount of planktonic cells within a growing culture were 
measured (Figure B-1). In the parental S613 strain, around 50% of cells aggregated 
during growth (Figure B-1.a). In Efc S613_D17C9, the cell line with elevated c-di-
AMP levels (Table 3.1), more than 90% of the cells aggregated during growth 
(Figure B-1.b). S613F_D17C9 also grew more slowly than wild type S613 and 
reached ~73% of the total cell density measured for S613 at stationary phase. 
However, when biofilm formation was measured using a crystal violet staining assay 
(O’Toole, 2011), I did not observe a statistically significant difference between the 
S613 and S613_D17C9 strains (data not show).  
 
 Figure B-1 Growth curves of Efc S613 and Efc S613_D17C9. Three independent 
cultures were measured for whole cell culture or planktonic cells separately. 
Planktonic cells are defined as those in the supernatant. The growth curves show S613 
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(A) and S613F_D17C9 (B) planktonic cells (blue) and whole cell cultures (black). The 
difference between the blue (planktonic) and black (total) illustrates the propensity of 
cells to aggregate. S613F_D17C9 grew slower and more cells aggregated compared 
with S613. Error bars correspond to standard deviations among three biological 
independent measurements. Please see Table 3.1 and Table 4.1 for strain details. 
 
